

Bibliography

1. Scientific full-length international papers

Online publications ahead of publication

463. Ghiti Moghadam M, Ten Klooster PM, Vonkeman HE, Kneepkens EL, Klaasen R, Stolk JN, Tchetverikov I, Vreugdenhil SA, van Woerkom JM, Goekoop-Ruiterman YPM, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL. Impact of Stopping Tumor Necrosis Factor-inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.; Dutch National POET Collaboration. *Arthritis Care Res* 2017 Jul 10. doi: 10.1002/acr.23315. [Epub ahead of print]

462. van Lunteren M, Ez-Zaitouni Z, Fongen C, Landewé R, Ramonda R, van der Heijde D, van Gaalen FA. Disease activity decrease is associated with improvement in work productivity over 1 year in early axial spondyloarthritis (SPondyloArthritis Caught Early cohort). *Rheumatology (Oxford)*. 2017 Dec 1;56(12):2222-2228. doi: 10.1093/rheumatology/kex365.

461. Fernandes S, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Dougados M, Moltó A. Vitamin D status in spondyloarthritis: results of the ASAS-COMOSPA international study. *Clin Exp Rheumatol*. 2017 Nov 16. [Epub ahead of print]

460. Bautista-Molano W, Landewé R, Burgos-Vargas R, Maldonado-Cocco J, Moltó A, van den Bosch F, Valle-Oñate R, Dougados M, van der Heijde D. Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study. *J Rheum* 2018 DOI: 10.3899/jrheum.170520

459. Nikiphorou E, Ramiro S, van der Heijde D, Norton S, Moltó A, Dougados M, van den Bosch F, Landewé R; ASAS-COMOSPA Task Force. Comorbidities in Spondyloarthritis associate with poor function, work disability and quality of life: Results from the ASAS-COMOSPA study. *Arthritis Care Res (Hoboken)*. 2017 Nov 10. doi: 10.1002/acr.23468. [Epub ahead of print]

458. van der Heijde D, Landewé R. Should radiographic progression still be used as outcome in RA? *Clin Immunology* 2017 <https://doi.org/10.1016/j.clim.2017.07.022>

457. van der Heijde D, Baraliakos X, Hermann K-GA, Landewé RBM, Machado PM, Maksymowych WP, Davies OR, de Peyrecave N, Hoepken B, Bauer L, Nurminen T, Braun J. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. *Ann Rheum Dis* 2018 Online first

456. Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, Janknegt R, Peeters R, Landewé RBM, Winkens B, van Bodegraven AA. The nocebo effect challenges the non-medical infliximab switch in practice. *Eur J Clin Pharmacol*. 2018 Jan 24. doi: 10.1007/s00228-018-2418-4. [Epub ahead of print]

2018

455. Nikiphorou E, van der Heijde D, Norton S, Landewé RBM, Molto A, Dougados M, Van den Bosch FE, Ramiro S. Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study. *Ann Rheum Dis* 2018;77:405–11

454. Dougados M, Maksymowych WP, Landewé RBM, Moltó A, Claudepierre P, de Hooge M, Lambert RG, Bonin R, Bukowski JF, Jones HE, Logeart I, Pedersen R, Szumski A, Vlahos B, van der Heijde D. Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARC trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis. *Ann Rheum Dis* 2018;77:221–27

453. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DG, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, de Wit M, Aletaha D, Baraliakos X, Betteridge N, van den Bosch F, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, de Vlam K, van der Heijde D. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann Rheum Dis* 2018;77:3-17

452. Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewé RBM, van der Heijde D, Ciurea A. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. *Ann Rheum Dis* 2018;77:63-9

451. Molto A, Gossec L, Meghnathi B, Landewé RBM, van der Heijde D, Atagunduz P, Elzorkany BK, Akkoc N, Kiltz U, Gu, J, Wei JJC, Dougados M. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. *Ann Rheum Dis* 2018;77:124-7

2017

450. Burmester GR, Landewé R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. *Ann Rheum Dis* 2017;76:414-7

449. Peterfy C, Strand V, Tian L, Østergaard M, Lu Y, DiCarlo J, Countryman P, Deodhar A, Landewé R, Ranganath VK, Troum O, Conaghan PG. Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials. *Ann Rheum Dis* 2017;76:992-7

448. Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R, Dougados M, Emery P, Ferraccioli G, Fonseca J, Raza K, Silva-Fernández L, Smolen JS, Skingle D, Szekanecz Z, Kvien TK, van der Helm-van Mil A, van Vollenhoven R. 2016 update of the EULAR recommendations for the management of early arthritis. *Ann Rheum Dis* 2017;76:948-59

447. van Steenbergen HW, Aletaha D, Beart-van de Voorde LJ, Brouwer E, Codreanu C, Combe B, Fonseca JE, Hetland ML, Humby F, Kvien TK, Niedermann K, Nuño L, Oliver S, Rantapää-Dahlqvist S, Raza K, van Schaardenburg D, Schett G, De Smet L, Szücs G, Vencovský J, Wiland P, de Wit M, Landewé RL, van der Helm-van Mil AH. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. *Ann Rheum Dis* 2017;76:491-6

446. Bergstra SA, Allaart CF, Stijnen T, Landewé RBM. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients. *Arthritis Care Res* 2017;69:1473-83

445. Turina MC, Yeremenko N, van Gaalen F, van Oosterhout M, Berg IJ, Ramonda R, Lebre CM, Landewé R, Baeten D. Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the

SpondyloArthritis Caught Early (SPACE) cohort.
RMD Open. 2017;3:e000319

444. Daien CI, Hua C, Combe B, Landewe R. Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis.
RMD Open. 2017;3:e000404

443. Hua C, Daien CI, Combe B, Landewe R. Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis.
RMD Open. 2017;3:e000406

442. Bouman CA, den Broeder AA, van der Maas A, van den Hoogen FH, Landewé RB, van Herwaarden N. What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?
RMD Open. 2017;3:e000327

441. Mahmood S, van Oosterhout M, de Jong S, Landewé R, van Riel P, van Tuyl LHD. Evaluating quality of care in rheumatoid arthritis: the patient perspective.
RMD Open. 2017;3:e000411

440. Bergstra SA, Olivas O, Akdemir G, Riyazi N, Collée G, van Groenendael JHLM, Landewé RBM, Allaart CF. Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.
Arthritis Res Ther. 2017;19:220

439. Bergstra SA, Landewé RBM, Huizinga TWJ, Allaart CF. Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy..Rheumatology (Oxford). 2017 Oct 1;56(10):1721-1728. doi: 10.1093/rheumatology/kex236.

438. Burgers LE, Siljehult F, Ten Brinck RM, van Steenberg HW, Landewé RBM, Rantapää-Dahlqvist S, van der Helm-van Mil AHM. Validation of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.
Rheumatology 2017;56:2123-28

437. Bergstra SA, Allaart CF, van den Berg R, Chopra A, Govind N, Huizinga TWJ, Landewe RBM. Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
Arthritis Res Ther. 2017;19:258

436. de Bruin F, ter Horst S, Bloem JL, van den Berg R, de Hooge M, van Gaalen F, Dagfinrud H, van Oosterhout M, Landewé R, van der Heijde D, Reijniere M. Prevalence and clinical significance of lumbosacral transitional vertebra (LSTV) in a young back pain population with suspected axial spondyloarthritis: results of the SpondyloArthritis Caught Early (SPACE) cohort.
Skeletal Radiol 2017;46:633–9

435. van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
Rheumatology 2017;56:1498-509

434. Ez-Zaitouni Z, Hilkens A, Gossec L, Berg IJ, Landewé R, Ramonda R, Dougados M, van der Heijde D, van Gaalen F. Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts.
Arthritis Res Ther 2017;19:118

433. Braun J, Baraliakos X, Hermann KG, Landewé R, Machado PM, Maksymowych WP, Davies O, Hoepken B, Nurminen T, Stach C, van der Heijde D. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.
432. de Hooge M, de Bruin F, de Beer L, Bakker P, van den Berg R, Ramiro S, van Gaalen F, Fagerli K, Landewé R, van Oosterhout M, Ramonda R, Huizinga T, Bloem H, Reijnierse M, van der Heijde D. Is site of back pain related to location of MRI lesion in patients with chronic back pain included in the SPACE-cohort? *Arthritis Care Res* 2017;69:717-23
431. Bautista-Molano W, Landewé RB, Serna C, Valle-Oñate R, van der Heijde D. Factors associated with the decision of the rheumatologist to order sacroiliac joints magnetic resonance imaging (SI-MRI) or HLA-B27 testing in the diagnostic work-up of patients with spondyloarthritis in clinical practice. *Clin Exp Rheumatol.* 2017;35:122-8
430. Bautista-Molano W, van der Heijde D, Landewé R, Lafaurie GI, de Ávila J, Valle-Oñate R, Romero-Sanchez C. Is there a relationship between spondyloarthritis and periodontitis? A case-control study. *RMD Open* 2017;3:e000547
429. Dougados M, Sepriano A, Molto A, van Lunteren M, Ramiro S, de Hooge M, van den Berg R, Navarro Compan V, Demattei C, Landewé R, van der Heijde D. Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. *Ann Rheum Dis* 2017;76:1823-8
428. Ez-Zaitouni Z, Bakker PAC, van Lunteren M, de Hooge M, van den Berg R, Reijnierse M, Fagerli KM, Landewé RBM, Ramonda R, Jacobsson LTH, Saraux A, Lenczner G, Feydy A, Pialat JB, Thévenin F, van Gaalen FA, van der Heijde D. The yield of a positive MRI of the spine as imaging criterion in the ASAS classification criteria for axial spondyloarthritis: results from the SPACE and DESIR cohorts. *Ann Rheum Dis* 2017; 76:1731-6
427. Bakker P, Moltó A, Etcheto A, Van den Bosch F, Landewé R, van Gaalen F, Dougados M, van der Heijde D. The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study. *Arthritis Res Ther* 2017:19:96
426. Ez-Zaitouni Z, Bakker PAC, van Lunteren M, Berg IJ, Landewé R, van Oosterhout M, Lorenzin M, van der Heijde D, van Gaalen FA. Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort. *Ann Rheum Dis* 2017;76:1086-92
425. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgerit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg J-E, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien TK, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis* 2017;76:960-77
424. Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, Bijlsma JW, Burmester GR, Dougados M, Scholte-Voshaar M, van Vollenhoven R, Landewé R. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis* 2017;76:1113-36
423. Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, Scholte-Voshaar M, Falzon L, Landewé RBM. Safety of synthetic and

biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.

Ann Rheum Dis 2017;76:1101-36

422. Chatzidionysiou K, Emamikia S, Nam J, Ramiro S, Smolen J, van der Heijde D, Dougados M, Bijlsma J, Burmester G, Scholte M, van Vollenhoven R, Landewé R. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.

Ann Rheum Dis 2017;76:1102-07

421. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.

Ann Rheum Dis 2017;76:978-91

420. Sepriano A, Rubio R, Ramiro S, Landewé R, van der Heijde D. Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis.

Ann Rheum Dis 2017;76:886-90

419. Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landewé R, Van den Bosch F, Falzon L, Ramiro S. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.

RMD Open 2017;3:e000397-e000397

418. Sepriano A, Regel A, van der Heijde D, Braun J, Baraliakos X, Landewé R, Van den Bosch F, Falzon L, Ramiro S. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.

RMD Open 2017;3:e000396-e000396

2016

417. Gvozdenović E, Wolterbeek R, van der Heijde D, Huizinga T, Allaart C, Landewé R. DAS steered therapy in clinical practice; cross-sectional results from the METEOR database.

BMC Musculoskelet Disord. 2016 Jan 16;17:33

416. de Winter JJ, van Mens LJ, van der Heijde D, Landewé R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis.

Arthritis Res Ther 2016;18:196

415. Essers I, Ramiro S, Stolwijk C, Blaauw M, Landewé R, van der Heijde D, van den Bosch F, Dougados M, van Tubergen A. Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS.

Clin Exp Rheumatol 2016;34:214-21

414. van der Heijde D, Landewé RB, Mease PJ, McInnes IB, Conaghan PG, Pricop L, Ligozio G, Richards HB, Mpofo S. Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.

Arthritis Rheumatol 2016;68:1914-2

413. Bautista-Molano W, Landewé RBM, Londoño J, Romero-Sanchez C, Valle-Oñate R, van der Heijde D. Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis.

Clin Rheumatol 2016;35:1759-67

412. Kviatkovsky MJ, Ramiro S, Landewé R, Dougados M, Tubach F, Bellamy N, Hochberg M, Ravaud P, Martin-Mola E, Awada H, Bombardier C, Felson D, Hajjaj-Hassouni N, Logeart I, Matucci-Cerinic M, van de Laar M, van der Heijde D. The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. *J Rheumatol* 2016;43:1680-6
411. Essers I, Boonen A, Busch M, van der Heijde D, Keszei AP, Landewé R, Ramiro S, van Tubergen A. Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. *Rheumatology* 2016;55:2014-22
410. van Genderen S, Plasqui G, Landewé R, Lacaille D, Arends S, van Gaalen F, van der Heijde D, Heuft L, Luime J, Spoorenberg A, Gignac M, Boonen A. Social Role Participation in Patients With Ankylosing Spondylitis: A Cross-Sectional Comparison With Population Controls. *Arthritis Care Res* 2016;68:1899-1905
409. Sepriano A, Ramiro S, van der Heijde D, Ávila-Ribeiro P, Fonseca R, Borges J, Teixeira L, Carvalho PD, Cerqueira M, Neves J, Meirinhos T, Barcelos A, Sequeira G, Salvador MJ, Canas da Silva J, Santos H, Bernardes M, Vieira-Sousa E, Canhão H, Branco JC, Pimentel-Santos F, Landewé R. Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study. *Arthritis Rheum* 2016;68:2671-9
408. Bakker PA, Ez-Zaitouni Z, van Lunteren M, van den Berg R, de Hooge M, Fagerli KM, Landewé R, van Oosterhout M, Ramonda R, Reijnierse M, van der Heijde D, van Gaalen FA. Are additional tests needed to rule out axial spondyloarthritis in patients ages 16-45 years with short-duration chronic back pain and maximally one spondyloarthritis feature? *Arthritis Care Res* 2016;68:1726-30
407. Lambert RGW, Bakker PAC, van der Heijde D, Weber U, Rudwaleit M, Hermann K-GA, Sieper J, Baraliakos X, Bennett A, Braun J, Burgos-Vargas R, Dougados M, Pedersen SJ, Jurik AG, Maksymowych WP, Marzo-Ortega H, Østergaard M, Poddubnyy D, Reijnierse M, van den Bosch F, van der Horst-Bruinsma I, Landewé R. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. *Ann Rheum Dis* 2016;75:1958-63
406. Landewé RBM, Connell CA, Bradley JD, Wilkinson B, Gruben D, Strengholt S, van der Heijde D. Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials. *Arthritis Research & Therapy* 2016;18:212 DOI: 10.1186/s13075-016-1106-y
405. Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewé R. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. *Ann Rheum Dis* 2016;75:1486-93
404. Putrik P, Ramiro S, Lie E, Keszei AP, Kvien TK, van der Heijde D, Landewé R, Uhlig T, Boonen A. Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. *Rheumatology* 2016;55:1217-24
403. Markus IM, Landewé R, Wolterbeek R, Ho M, Jenkins M, van der Heijde D. Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis. *Rheumatology* 2016;7:1295-3000
402. Rubio Vargas R, van den Berg R, van Lunteren M, Ez-Zaitouni Z, Bakker PAC, Dagfinrud H, Ramonda R, Landewé R, Molenaar E, van Gaalen FA, van der Heijde D. Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?: Data from the SPACE cohort. *RMD Open* 2016; 2:e000283, doi:10.1136/rmdopen-2016-000283

402. de Hooge M, van den Berg R, Navarro-Compán V, Reijnen M, van Gaalen F, Fagerli K, Landewé R, van Oosterhout M, Ramonda R, Huizinga T, van der Heijde D. Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?
Ann Rheum Dis 2016;75:1308-14
401. Sepriano A, Landewé R, van der Heijde D, Sieper J, Akkoc N, Brandt J, Braun J, Collantes-Estevez E, Dougados M, Fitzgerald O, Huang F, Gu J, Kirazli Y, Maksymowych WP, Marzo-Ortega H, Olivieri I, Özgöçmen S, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Van den Bosch F, van der Horst-Bruinsma I, Weber U, Wei J, Rudwaleit M. Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis.
Ann Rheum Dis 2016;75:1034-42
400. Moltó A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, Burgos-Vargas R, Cheung PP, Collantes-Estevez E, Deodhar A, El-Zorkany B, Erdes S, Gu J, Hajjaj-Hassouni N, Kiltz U, Kim T-H, Kishimoto M, Luo S-F, Machado PM, Maksymowych WP, Maldonado-Cocco J, Marzo-Ortega H, Montecucco C-M, Ozgöçmen S, van Gaalen F, Dougados M. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study.
Ann Rheum Dis 2016; 75:1016-23
399. Gossec L, Portier A, Landewé R, Etcheto A, Navarro-Compán V, Kroon F, van der Heijde D, Dougados M. Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative.
Ann Rheum Dis 2016;75:991-6
398. Gvozdenovic E, Allaart CF, van der Heijde D, Ferraccioli G, Smolen JS, Huizinga TWJ, Landewé R. When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS).
RMD Open 2016;2:e000221.doi:10.1136/rmdopen-2015-000221
397. van der Heijde D, Landewé R. Are conventional radiographs still of value?
Curr Opin Rheum 2016;28:310-5
396. Landewé R, van der Heijde D. New concepts of clinical trials in rheumatoid arthritis: a boom of noninferiority trials.
Curr Opin Rheum 2016;28:316-22
395. Castillo-Ortiz JD, Ramiro S, Landewé R, van der Heijde D, Dougados M, van den Bosch F, Boonen A. Work Outcome in Patients With Ankylosing Spondylitis: Results From a 12-Year Followup of an International Study.
Arthritis Care Res 2016;68:544-52
394. Navarro-Compán V, Ramiro S, Landewé R, Dougados M, Miceli-Richard C, Richette P, van der Heijde D. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort.
Ann Rheum Dis 2016;75:874-8
393. Webers C, Essers I, Ramiro S, Stolwijk C, Landewé R, van der Heijde D, van den Bosch F, Dougados M, van Tubergen A. Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study.
Rheumatology 2016;55:419-28
392. Kroon FP, van der Burg LR, Ramiro S, Landewé RB, Buchbinder R, Falzon L, van der Heijde D. Non-steroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review.
J Rheumatol 2016;43:607-17
391. de Bruin F, Ter Horst S, Bloem HL, van den Berg R, de Hooge M, van Gaalen F, Fagerli KM, Landewé R, van Oosterhout M, van der Heijde D, Reijnen M. Prevalence of degenerative changes of the spine on

magnetic resonance images and radiographs in patients aged 16-45 years with chronic back pain of short duration in the Spondyloarthritis Caught Early (SPACE) cohort.
Rheumatology 2016;55:56-65

390. de Bruin F, Ter Horst S, van den Berg R, de Hooge M, van Gaalen F, Fagerli KM, Landewé R, van Oosterhout M, Bloem JL, van der Heijde D, Reijnen M. Signal intensity loss of the intervertebral discs in the cervical spine of young patients on fluid sensitive sequences.
Skeletal Radiol 2016;45:375-81

389. Gherghe AM, Ramiro S, Landewé R, Mihai C, van der Heijde D. Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials.
RMD Open 2016;2:e000219.doi:10.1136/rmdopen-2015-000219

388. Mihai C, Landewé R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM, Ionescu R, Rednic S, Allanore Y, Avouac J, Czirják L, Hachulla E, Riemekasten G, Cozzi F, Airò P, Cutolo M, Mueller-Ladner U, Matucci-Cerinic M, EUSTAR co-authors. Digital ulcers predict a worse disease course in patients with systemic sclerosis.
Ann Rheum Dis 2016;75:681-6

387. Ramiro S, Smolen JS, Landewé R, van der Heijde D, Dougados M, Emery P, de Wit M, Cutolo M, Oliver S, Gossec L. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.
Ann Rheum Dis 2016;75:490-8

386. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Ann Rheum Dis 2016;75:499-510

385. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Victoria Navarro-Compán M, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewé R, Martin-Mola E, Nash P, Østergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Ann Rheum Dis 2016;75:3-15

384. van Genderen S, Plasqui G, Lacaille D, Arends, S van Gaalen F, van der Heijde D, Heuft L, Keszei A, Luime, J Spoorenberg A, Landewé R, Gignac M, Boonen A. Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity.
RMD Open 2016; 2:e000177

2015

383. Bergstra SA, Markusse IM, Akdemir G, Runday HK, Han KH, Lems WF, Kerstens PJ, van den Berg R, Landewé RB, Allaart CF. Erosions in the foot at baseline are predictive of orthopaedic shoe use after 10 years of treat to target therapy in patients with recent onset rheumatoid arthritis.
Clin Rheumatol 2015 Dec 22. [Epub ahead of print]

382. Mahmood S, Lesuis N, van Tuyl LH, van Riel P, Landewé R. Quality in rheumatoid arthritis care.
Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4-5):664-79. Review.

381. Ramiro S, Smolen JS, Landewé R, van der Heijde D, Dougados M, Emery P, de Wit M, Cutolo M, Oliver

S, Gossec L. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis*. 2015 Dec 11. pii: annrheumdis-2015-208466. doi: 10.1136/annrheumdis-2015-208466. [Epub ahead of print]

380. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis*. 2015 Dec 7. pii: annrheumdis-2015-208337. doi: 10.1136/annrheumdis-2015-208337. [Epub ahead of print]

379. van Genderen S, Boonen A, van der Heijde D, Heuft L, Luime J, Spoorenberg A, Arends S, Landewé R, Plasqui G. Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls. *J Rheumatol*. 2015 Dec;42(12):2369-75.

378. de Bruin F, Ter Horst S, van den Berg R, de Hooge M, van Gaalen F, Fagerli KM, Landewé R, van Oosterhout M, Bloem JL, van der Heijde D, Reijnierse M. Signal intensity loss of the intervertebral discs in the cervical spine of young patients on fluid sensitive sequences. *Skeletal Radiol*. 2015 Dec 4. [Epub ahead of print]

377. Ramiro S, Landewé R, van der Heijde D, Harrison D, Collier D, Michaud K. Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors? *RMD Open*. 2015 Nov 18;1(1):e000155. doi: 10.1136/rmdopen-2015-000155. eCollection 2015.

376. Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewé R. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. *Ann Rheum Dis*. 2015 Oct 13. pii: annrheumdis-2015-208011. doi: 10.1136/annrheumdis-2015-208011. [Epub ahead of print]

375. van der Burg LR, van Amelsvoort LG, Boonen A, Jansen N, Kant IJ, Landewé RB. Cardiovascular Morbidity and Mortality Among Working Individuals With Rheumatic Disease: Results From a Large Prospective Cohort Study. *J Clin Rheumatol*. 2015 Oct;21(7):359-63.

374. Gvozdrenović E, Wolterbeek R, Allaart CF, Brenol C, Dougados M, Emery P, Ferraccioli G, van der Heijde D, Huizinga TW, Kay J, Martin Mola E, Moots RJ, da Silva JA, Smolen J, Veale D, Landewé RB. Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database. *J Clin Rheumatol*. 2015 Oct;21(7):349-54.

373. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofo S; FUTURE 1 Study Group. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. *N Engl J Med*. 2015 Oct;373(14):1329-39.

372. Castillo-Ortiz JD, Ramiro S, Landewé R, van der Heijde D, Dougados M, van den Bosch F, Boonen A. Work outcome in patients with Ankylosing Spondylitis: results of 12-year follow-up of OASIS. *Arthritis Care Res (Hoboken)*. 2015 Sep 28. doi:10.1002/acr.22730. [Epub ahead of print]

371. van Eijk-Hustings Y, Kroese M, Creemers A, Landewé R, Boonen A. Resource utilisation and direct costs in patients with recently diagnosed fibromyalgia who are offered one of three different interventions in a randomised pragmatic trial.

Clin Rheumatol. 2015 Sep 26. [Epub ahead of print]

370. Navarro-Compán V, Ramiro S, [Landewé R](#), Dougados M, Miceli-Richard C, Richette P, van der Heijde D. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. *Ann Rheum Dis*. 2015 Sep 24. pii: annrheumdis-2015-207786. doi: 10.1136/annrheumdis-2015-207786. [Epub ahead of print]

369. Navarro-Compán V, de Miguel E, van der Heijde D, [Landewé R](#), Almodóvar R, Montilla C, Beltrán E, Zarco P. Spondyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort. *Arthritis Res Ther*. 2015 Sep 23;17:265. doi: 10.1186/s13075-015-0779-y.

368. Webers C, Essers I, Ramiro S, Stolwijk C, [Landewé R](#), van der Heijde D, van den Bosch F, Dougados M, van Tubergen A. Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. *Rheumatology (Oxford)*. 2015 Sep 18.pii: kev340. [Epub ahead of print]

367. Smolen JS, van Vollenhoven R, Kavanaugh A, Strand V, Vencovsky J, Schiff M, [Landewé R](#), Haraoui B, Arendt C, Mountian I, Carter D, van der Heijde D. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. *Arthritis Res Ther*. 2015 Sep 10;17:245. doi: 10.1186/s13075-015-0767-2.

366. Ramiro S, [Landewé R](#), van Tubergen A, Boonen A, Stolwijk C, Dougados M, van den Bosch F, van der Heijde D. Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. *RMD Open*. 2015 Sep 14;1(1):e000153. doi:10.1136/rmdopen-2015-000153.

365. Gherghe AM, Dougados M, Combe B, [Landewé R](#), Mihai C, Berenbaum F, Mariette X, Wolterbeek R, van der Heijde D. Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. *RMD Open*. 2015 Sep 14;1(1):e000128. doi: 10.1136/rmdopen-2015-000128.

364. Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczyński P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, [Landewé R](#), de Longueville M, Hoepken B, Peterson L, van der Heijde D. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. *RMD Open* 2015 Jun 25;1(1):e000119. doi: 10.1136/rmdopen-2015-000119. eCollection 2015.

363. Moltó A, Etcheto A, van der Heijde D, [Landewé R](#), van den Bosch F, Bautista Molano W, Burgos-Vargas R, Cheung PP, Collantes-Estevez E, Deodhar A, El-Zorkany B, Erdes S, Gu J, Hajjaj-Hassouni N, Kiltz U, Kim TH, Kishimoto M, Luo SF, Machado PM, Maksymowych WP, Maldonado-Cocco J, Marzo-Ortega H, Montecucco CM, Ozgocmen S, van Gaalen F, Dougados M. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. *Ann Rheum Dis*. 2015 Oct 21. pii: annrheumdis-2015-208174. doi: 10.1136/annrheumdis-2015-208174. [Epub ahead of print].

362. Boone NW, Teeuwisse P, van der Kuy PH, Janknegt R, [Landewé RB](#). Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs). *Springerplus*. 2015 Aug 28;4:462. doi: 10.1186/s40064-015-1247-5. eCollection 2015.

361. de Hooge M, van den Berg R, Navarro-Compán V, Reijniere M, van Gaalen F, Fagerli K, [Landewé R](#), van Oosterhout M, Ramonda R, Huizinga T, van der Heijde D. Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?

Ann Rheum Dis. 2015 Aug 18. pii: annrheumdis-2015-207823. doi: 10.1136/annrheumdis-2015-207823. [Epub ahead of print]

360. de Bruin F, Ter Horst S, Bloem HL, van den Berg R, de Hooge M, van Gaalen F, Fagerli KM, Landewé R, van Oosterhout M, van der Heijde D, Reijnen M. Prevalence of degenerative changes of the spine on magnetic resonance images and radiographs in patients aged 16-45 years with chronic back pain of short duration in the Spondyloarthritis Caught Early (SPACE) cohort. *Rheumatology (Oxford)*. 2015 Aug 14. pii: kev283. [Epub ahead of print]

359. Turina MC, Ramiro S, Baeten DL, Mease P, Paramarta JE, Song IH, Pangan AL, Landewé R. A psychometric analysis of outcome measures in peripheral spondyloarthritis. *Ann Rheum Dis*. 2015 Aug 5. pii: annrheumdis-2014-207235. doi: 10.1136/annrheumdis-2014-207235. [Epub ahead of print]

358. Aalbers C, Gerlag D, Vos K, Vervoordeldonk M, Landewé R, Tak PP. Intra-articular etanercept treatment in inflammatory arthritis: A randomized double-blind placebo-controlled proof of mechanism clinical trial validating TNF as a potential therapeutic target for local treatment. *Joint Bone Spine*. 2015 Jul 15. pii: S1297-319X(15)00120-7. doi: 10.1016/j.jbspin.2015.03.002. [Epub ahead of print]

357. Kroon FP, van der Burg LR, Ramiro S, Landewé RB, Buchbinder R, Falzon L, van der Heijde D. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). *Cochrane Database Syst Rev*. 2015 Jul 17;7:CD010952. doi: 10.1002/14651858.CD010952.pub2. Review.

356. Maksymowych WP, Boire G, van Schaardenburg D, Wichuk S, Turk S, Boers M, Siminovitch KA, Bykerk V, Keystone E, Tak PP, van Kuijk AW, Landewé R, van der Heijde D, Murphy M, Marotta A. 14-3-3 η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. *J Rheumatol*. 2015 Sep;42(9):1587-94. doi: 10.3899/jrheum.141385. Epub 2015 Jul 15.

355. Aalbers CJ, Gerlag DM, Vervoordeldonk MJ, Tak PP, Landewé RB. Single-joint Assessment for the Evaluation of Intraarticular Treatment: Responsiveness and Discrimination of the Composite Change Index. *J Rheumatol*. 2015 Sep;42(9):1672-6. doi: 10.3899/jrheum.140956. Epub 2015 Jul 15.

354. Kloppenburg M, Bøyesen P, Visser AW, Haugen IK, Boers M, Boonen A, Conaghan PG, Hawker GA, Kvien TK, Landewé R, Uhlig T, Smeets W, Greibrokk E, van der Heijde DM. Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. *J Rheumatol*. 2015 Jul 1. pii: jrheum.141017. [Epub ahead of print]

353. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2015 Jun 26. pii: S0140-6736(15)61134-5. doi: 10.1016/S0140-6736(15)61134-5. [Epub ahead of print]

352. Landewé R, van Tubergen A. Clinical Tools to Assess and Monitor Spondyloarthritis. *Curr Rheumatol Rep*. 2015 Jul;17(7):47. doi: 10.1007/s11926-015-0522-3.

351. van Durme CM, Wechalekar MD, Landewé RB. Nonsteroidal anti-inflammatory drugs for treatment of acute gout. *JAMA*. 2015 Jun 9;313(22):2276-7.

350. Landewé R, Smolen JS, Florentinus S, Chen S, Guérette B, van der Heijde D. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis.

Arthritis Res Ther. 2015 May 21;17:133. doi: 10.1186/s13075-015-0626-1.

349. Poddubnyy D, van Tubergen A, [Landewé R](#), Sieper J, van der Heijde D; Assessment of SpondyloArthritis international Society (ASAS). Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. *Ann Rheum Dis*. 2015 Aug;74(8):1483-7. doi: 10.1136/annrheumdis-2014-207151. Epub 2015 May 19. Review.

348. Ramiro S, [Landewé RB](#), van der Heijde D, Stolwijk C, Dougados M, van den Bosch F, van Tubergen A. Hierarchy of impairment of spinal mobility measures in ankylosing spondylitis: 12-year data from the OASIS cohort. *Arthritis Care Res (Hoboken)*. 2015; 67: 1571-7

347. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, [Landewé R](#), Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis*. 2016; 75: 3-15

346. van den Berg R, de Hooge M, Bakker PA, van Gaalen F, Navarro-Compán V, Fagerli KM, [Landewé R](#), van Oosterhout M, Ramonda R, Reijniere M, van der Heijde D. Metric Properties of the SPARCC Score of the Sacroiliac Joints - Data from Baseline, 3-month, and 12-month Followup in the SPACE Cohort. *J Rheumatol*. 2015; 42; 1186-93

345. Navarro-Compán V, Smolen JS, Huizinga TW, [Landewé R](#), Ferraccioli G, da Silva JA, Moots RJ, Kay J, van der Heijde D. Quality indicators in rheumatoid arthritis: results from the METEOR database. *Rheumatology (Oxford)*. 2015; 54:1630-9

344. Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, [Landewé R](#). Impact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritis. *Arthritis Care Res (Hoboken)*. 2015; 67: 1475-80

343. [Landewé RB](#). New analysis tools for observational studies. *Z Rheumatol*. 2015 Mar;74(2):113-118.

342. [Landewé RB](#). Conventional DMARDs in axial spondyloarthritis: wishful—rather than rational thinking! *Ann Rheum Dis*. 2015; 74: 951-3

341. Mihai C, [Landewé R](#), van der Heijde D, Walker UA, Constantin PI, Gherghe AM, Ionescu R, Rednic S, Allanore Y, Avouac J, Cziráj L, Hachulla E, Riemekasten G, Cozzi F, Airò P, Cutolo M, Mueller-Ladner U, Matucci-Cerinic M; EUSTAR co-authors. Digital ulcers predict a worse disease course in patients with systemic sclerosis. *Ann Rheum Dis*. 2015 Feb 16. pii: annrheumdis-2014-205897. doi: 10.1136/annrheumdis-2014-205897. [Epub ahead of print]

340. Smolen JS, Kay J, Doyle M, [Landewé R](#), Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Xu S, Zhou Y, Hsia EC. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. *Arthritis Res Ther*. 2015 Jan 22;17(1):14. doi: 10.1186/s13075-015-0516-6.

339. Sieper J, [Landewé R](#), Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, Braun J, Deodhar A, Kivitz A, Walsh J, Hoepken B, Nurminen T, Maksymowych WP. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.

Arthritis Rheumatol. 2015 Mar;67(3):668-77.

338. Deodhar A, Sieper J, Reveille JD, van der Heijde D, Gensler LS, Landewé R; Spondyloarthritis Research and Treatment Network and Assessment of SpondyloArthritis international Society authors. Reply: To PMID 25154344.

Arthritis Rheumatol. 2015 Mar;67(3):856-7..

337. Navarro-Compán V, Gherghe AM, Smolen JS, Aletaha D, Landewé R, van der Heijde D. Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review.

Rheumatology (Oxford). 2014; 54:994-1007

336. van den Berg R, van der Heijde D, Landewé R, van Lambalgen K, Huizinga T. The METEOR initiative: the way forward for optimal, worldwide data integration to improve care for RA patients.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-135-40.

335. Landewé RB, van der Heijde D. Optimisation of rheumatic disease assessments in clinical trials, clinical care, and long-term databases.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-2-6.

334. Essers I, Ramiro S, Stolwijk C, Blaauw M, Landewé R, van der Heijde D, Van den Bosch F, Dougados M, van Tubergen A. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology (Oxford). 2015 Apr;54(4):633-40.

333. van Onna M, van Tubergen A, Jurik AG, van der Heijde D, Landewé R. Natural course of bone marrow oedema on magnetic resonance imaging of the sacroiliac joints in patients with early inflammatory back pain: a 2-year follow-up study.

Scand J Rheumatol. 2015;44(2):129-34.

332. Stolwijk C, Ramiro S, Vosse D, Landewé R, van der Heijde D, van Tubergen A. Comparison of tests for lumbar flexion and hip function in patients with and without axial spondyloarthritis. Arthritis Care Res (Hoboken). 2015Apr;67(4):538-45.

2014

331. van den Berg R, van der Heijde D, Landewé R, van Lambalgen K, Huizinga T. The METEOR initiative: the way forward for optimal, worldwide data integration to improve care for RA patients. Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-135-40

330. Landewé RB, van der Heijde D. Optimisation of rheumatic disease assessments in clinical trials, clinical care, and long-term databases.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-2-6.

329. Machado P, Navarro-Compán V, Landewé R, van Gaalen FA, Roux C, van der Heijde D. Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR cohort.

Arthritis Rheumatol. 2015 Feb;67(2):408-13.

328. Essers I, Ramiro S, Stolwijk C, Blaauw M, Landewé R, van der Heijde D, Van den Bosch F, Dougados M, van Tubergen A. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS.

Rheumatology (Oxford). 2015 Apr;54(4):633-40.

327. van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB. Non-steroidal anti-inflammatory drugs for acute gout.

Cochrane Database Syst Rev. 2014 Sep 16;9:CD010120. doi: 10.1002/14651858.CD010120.pub2. Review.

326. van Onna M, van Tubergen A, Jurik AG, van der Heijde D, Landewé R. Natural course of bone marrow oedema on magnetic resonance imaging of the sacroiliac joints in patients with early inflammatory back pain: a 2-year follow-up study. *Scand J Rheumatol*. 2015;44(2):129-34.
325. Stolwijk C, Ramiro S, Vosse D, Landewé R, van der Heijde D, van Tubergen A. Comparison of tests for lumbar flexion and hip function in patients with and without axial spondyloarthritis. *Arthritis Care Res (Hoboken)*. 2015 Apr;67(4):538-45.
324. van Echteld IA, van Durme C, Falzon L, Landewé RB, van der Heijde DM, Aletaha D. Treatment of gout patients with impairment of renal function: a systematic literature review. *J Rheumatol Suppl*. 2014 Sep;92:48-54.
323. Wechalekar MD, Vinik O, Moi JH, Sivera F, van Echteld IA, van Durme C, Falzon L, Bombardier C, Carmona L, Aletaha D, Landewé RB, van der Heijde DM, Buchbinder R. The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. *J Rheumatol Suppl*. 2014 Sep;92:15-25.
322. van Durme C, van Echteld IA, Falzon L, Aletaha D, van der Heijde DM, Landewé RB. Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: a systematic review of the literature. *J Rheumatol Suppl*. 2014 Sep;92:9-14.
321. Landewé RB. Editorial: how publication bias may harm treatment guidelines. *Arthritis Rheumatol*. 2014 Oct;66(10):2661-3.
320. Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, Clegg DO, Colbert RA, Gensler LS, van der Heijde D, van der Horst-Bruinsma IE, Inman RD, Maksymowych WP, Mease PJ, Raychaudhuri S, Reimold A, Rudwaleit M, Sieper J, Weisman MH, Landewé RB. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. *Arthritis Rheumatol*. 2014 Oct;66(10):2649-56.
319. Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, van Schaardenburg D, Boers M, Landewé R, van der Heijde D, Tak PP, Genovese MC, Weinblatt ME, Keystone EC, Zhukov OS, Abolhosn RW, Popov JM, Britsemmer K, van Kuijk AW, Marotta A. Serum 14-3-3 η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. *J Rheumatol*. 2014 Nov;41(11):2104-13.
318. Landewé RB, Smolen JS, Weinblatt ME, Emery P, Dougados M, Fleischmann R, Aletaha D, Kavanaugh A, van der Heijde D. Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. *Ann Rheum Dis*. 2014 Oct;73(10):1755-60.
317. Landewé R, Østergaard M, Keystone EC, Florentinus S, Liu S, van der Heijde D. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2015 Feb;67(2):180-6.
316. Navarro-Compán V, Landewé R, Provan SA, Ødegård S, Uhlig T, Kvien TK, Keszei AP, Ramiro S, van der Heijde D. Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. *Rheumatology (Oxford)*. 2015 Jan;54(1):83-90.
315. Ramiro S, van Tubergen A, van der Heijde D, Stolwijk C, Bookelman G, Dougados M, van den Bosch F, Landewé RB. Brief report: erosions and sclerosis on radiographs precede the subsequent development of

syndesmophytes at the same site: a twelve-year prospective followup of patients with ankylosing spondylitis.

Arthritis Rheumatol. 2014 Oct;66(10):2773-9.

314. Landewé RB, van der Heijde D. Comment on: 'comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial' by Qian-wen et al.

Ann Rheum Dis. 2014 Oct;73(10):e62. doi: 10.1136/annrheumdis-2014-206124. Epub 2014 Jul 10.

313. Bautista-Molano W, Navarro-Compán V, Landewé RB, Boers M, Kirkham JJ, van der Heijde D. How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review.

Clin Rheumatol. 2014 Sep;33(9):1313-22.

312. Ramiro S, van Tubergen A, Stolwijk C, van der Heijde D, Landewé R. Neutral lateral fingertip-to-floor distance can be derived from height.

Ann Rheum Dis. 2014 Sep;73(9):1748-9.

311. Gvozdenović E, Koevoets R, Langenhoff J, Allaart Cf, Landewé RB. Comparison of characteristics of international and national databases for rheumatoid arthritis: a systematic literature review.

Scand J Rheumatol. 2014;43(5):349-55.

310. Buch MH, Silva-Fernandez L, Carmona L, Aletaha D, Christensen R, Combe B, Emery P, Ferraccioli G, Guillemin F, Kvien TK, Landewé R, Pavelka K, Saag K, Smolen JS, Symmons D, van der Heijde D, Welling J, Wells G, Westhovens R, Zink A, Boers M. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.

Ann Rheum Dis. 2015; 74:963-9

309. Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, Landewé R. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.

Ann Rheum Dis. 2014 Aug;73(8):1455-61.

308. Maksymowych WP, van der Heijde D, Allaart CF, Landewé R, Boire G, Tak PP, Gui Y, Ghahary A, Kilani R, Marotta A. 14-3-3 η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage.

Arthritis Res Ther. 2014 Apr 21;16(2):R99. doi: 10.1186/ar4547.

307. van Onna M, van Tubergen A, van der Heijde DM, Jurik AG, Landewé R. Bone marrow edema on magnetic resonance imaging (MRI) of the sacroiliac joints is associated with development of fatty lesions on MRI over a 1-year interval in patients with early inflammatory low back pain: a 2-year followup study. J Rheumatol. 2014 Jun;41(6):1088-94.

306. Tugwell P, Boers M, D'Agostino MA, Beaton D, Boonen A, Bingham CO 3rd, Choy E, Conaghan PG, Dougados M, Duarte C, Furst DE, Guillemin F, Gossec L, Heiberg T, van der Heijde DM, Hewlett S, Kirwan JR, Kvien TK, Landewé RB, Mease PJ, Østergaard M, Simon L, Singh JA, Strand V, Wells G. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity.

J Rheumatol. 2014 May;41(5):1000-4.

305. Wells G, Beaton DE, Tugwell P, Boers M, Kirwan JR, Bingham CO 3rd, Boonen A, Brooks P, Conaghan PG, D'Agostino MA, Dougados M, Furst DE, Gossec L, Guillemin F, Helliwell P, Hewlett S, Kvien TK, Landewé RB, March L, Mease PJ, Ostergaard M, Simon L, Singh JA, Strand V, van der Heijde DM. Updating the OMERACT filter: discrimination and feasibility.

J Rheumatol. 2014 May;41(5):1005-10.

304. Ramiro S, van Tubergen A, Stolwijk C, van der Heijde D, Royston P, Landewé R. Reference intervals of spinal mobility measures in normal individuals: the mobility study.

Ann Rheum Dis. 2015; 74: 1218-24

303. Kirwan JR, Boers M, Hewlett S, Beaton D, Bingham CO 3rd, Choy E, Conaghan PG, D'Agostino MA, Dougados M, Furst DE, Guillemin F, Gossec L, van der Heijde DM, Kloppenburg M, Kvien TK, Landewé RB, Mackie SL, Matteson EL, Mease PJ, Merkel PA, Ostergaard M, Saketkoo LA, Simon L, Singh JA, Strand V, Tugwell P. Updating the OMERACT filter: core areas as a basis for defining core outcome sets. *J Rheumatol*. 2014 May;41(5):994-9.

302. Kirwan JR, Bartlett SJ, Beaton DE, Boers M, Bosworth A, Brooks PM, Choy E, de Wit M, Guillemin F, Hewlett S, Kvien TK, Landewé RB, Leong AL, Lyddiatt A, March L, May J, Montie PL, Nikai E, Richards P, Voshaar MM, Smeets W, Strand V, Tugwell P, Gossec L. Updating the OMERACT filter: implications for patient-reported outcomes. *J Rheumatol*. 2014 May;41(5):1011-5.

301. D'Agostino MA, Boers M, Kirwan J, van der Heijde D, Østergaard M, Schett G, Landewé RB, Maksymowych WP, Naredo E, Dougados M, Iagnocco A, Bingham CO 3rd, Brooks PM, Beaton DE, Gandjbakhch F, Gossec L, Guillemin F, Hewlett SE, Kloppenburg M, March L, Mease PJ, Moller I, Simon LS, Singh JA, Strand V, Wakefield RJ, Wells GA, Tugwell P, Conaghan PG. Updating the OMERACT filter: implications for imaging and soluble biomarkers. *J Rheumatol*. 2014 May;41(5):1016-24.

300. Boers M, Kirwan JR, Gossec L, Conaghan PG, D'Agostino MA, Bingham CO 3rd, Brooks PM, Landewé R, March L, Simon L, Singh JA, Strand V, Wells GA, Tugwell P. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0. *J Rheumatol*. 2014 May;41(5):1025-30.

299. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA, Conaghan PG, Bingham CO 3rd, Brooks P, Landewé R, March L, Simon LS, Singh JA, Strand V, Tugwell P. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. *J Clin Epidemiol*. 2014 Jul;67(7):745-53..

298. de Hair MJ, van de Sande MG, Ramwadhoebe TH, van der Leij C, Maas M, Hansson M, Klareskog L, Landewé R, Serre G, van Schaardenburg D, Gerlag DM, van Baarsen LG, Tak PP. Reply: To PMID 24574210. *Arthritis Rheumatol*. 2014 Jun;66(6):1683-4.

297. Maas T, Nieuwhof C, Passos VL, Robertson C, Boonen A, Landewé RB, Voncken JW, Knottnerus JA, Damoiseaux JG. Transgenerational occurrence of allergic disease and autoimmunity: general practice based epidemiological research. *Prim Care Respir J*. 2014 Mar;23(1):14-21.

296. van Onna M, van Tubergen A, van der Heijde D, Jurik AG, Landewé R. Gadolinium contrast-enhanced MRI sequence does not have an incremental value in the assessment of sacroiliitis in patients with early inflammatory back pain by using MRI in combination with pelvic radiographs: a 2-year follow-up study. *Clin Exp Rheumatol*. 2014 Mar-Apr;32(2):225-30.

2013

295. Ramiro S, van Tubergen A, van der Heijde D, van den Bosch F, Dougados M, Landewé R. How to deal with missing items in BASDAI and BASFI. *Rheumatology (Oxford)*. 2014; 53:374-6

294. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachet A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2013 Nov 23;382(9906):1705-13.

293. de Hair MJ, van de Sande MG, Ramwadhoebe TH, Hansson M, Landewé R, van der Leij C, Maas M, Serre G, van Schaardenburg D, Klareskog L, Gerlag DM, van Baarsen LG, Tak PP. Features of the synovium of individuals at risk of developing

rheumatoid arthritis: Implications for understanding preclinical rheumatoid arthritis.
Arthritis Rheumatol. 2014 Mar;66(3):513-22.

292. Stolwijk C, van Tubergen A, Ramiro S, Essers I, Blaauw M, van der Heijde D, Landewé R, van den Bosch F, Dougados M, Boonen A. Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitis.
Rheumatology (Oxford). 2014; 53:1054-64

291. Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A. Longterm Effect of Delaying Combination Therapy with Tumor Necrosis Factor Inhibitor in Patients with Aggressive Early Rheumatoid Arthritis: 10-year Efficacy and Safety of Adalimumab from the Randomized Controlled PREMIER Trial with Open-label Extension.
J Rheumatol. 2014: 41:5-14

290. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
Ann Rheum Dis. 2014: 73:39-47

289. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
Ann Rheum Dis. 2014: 73:492-509

288. Van den Berg R, de Hooge M, Rudwaleit M, Sieper J, van Gaalen F, Reijniere M, Landewé R, Huizinga T, van der Heijde D. ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort.
Ann Rheum Dis. 2013 Oct;72(10):1646-53.

287. De Hair MJ, Landewé RB, van de Sande MG, van Schaardenburg D, van Baarsen LG, Gerlag DM, Tak PP. Smoking and overweight determine the likelihood of developing rheumatoid arthritis.
Ann Rheum Dis. 2013 Oct;72(10):1654-8.

285. Durnez A, Paternotte S, Fechtenbaum J, Landewé RB, Dougados M, Roux C, Briot K. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study.
J Rheumatol. 2013 Oct;40(10):1712-8.

284. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs.
Ann Rheum Dis. 2014; 73:3-5

283. Gvozdenović E, Koevoets R, Wolterbeek R, van der Heijde D, Huizinga TW, Allaart CF, Landewé RB. Assessment of global disease activity in RA patients monitored in the METEOR database: the patient's versus the rheumatologist's opinion.
Clin Rheumatol. 2014: 461-6

282. Van Eijk-Hustings Y, Kroese M, Boonen A, Bessems-Beks M, Landewé R. Predictors for health improvement in patients with fibromyalgia: a 2-year follow-up study.
Clin Rheumatol. 2014; 34:133-41

281. Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F, Landewé R. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS

study.

Ann Rheum Dis. 2015; 74:52-9

280. Van der Burg LR, Boonen A, van Amelsvoort LG, Jansen NW, Landewé RB, Kant I. The effects of cardiovascular co-morbidities on work participation in rheumatic diseases: A prospective cohort study among working individuals.

Arthritis Care Res (Hoboken). 2014; 66:157-63

279. Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P, Shaughnessy L, Vanlunen B, van der Heijde D. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis. 2014; 73: 2094-100

278. Biliavska I, Stamm TA, Martinez-Avila J, Huizinga TW, Landewé RB, Steiner G, Aletaha D, Smolen JS, Machold KP. Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort. Ann Rheum Dis. 2013 Aug;72(8):1335-41.

277. Navarro-Compán V, Landewé R, Ahmad HA, Miller CG, Xu D, Wolterbeek R, van der Heijde D. Rate of adjudication of radiological progression in rheumatoid arthritis randomized controlled trials depending on preset limits of agreement: a pooled analysis from 15 randomized trials. Rheumatology (Oxford). 2013 Aug;52(8):1404-7.

276. Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014, 73:1811-8

275. Sivera F, Andrés M, Carmona L, Kydd AS, Moi J, Seth R, Sriranganathan M, van Durme C, van Echteld I, Vinik O, Wechalekar MD, Aletaha D, Bombardier C, Buchbinder R, Edwards CJ, Landewé RB, Bijlsma JW, Branco JC, Burgos-Vargas R, Catrina AI, Elewaut D, Ferrari AJ, Kiely P, Leeb BF, Montecucco C, Müller-Ladner U, Ostergaard M, Zochling J, Falzon L, van der Heijde DM. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014, 73:328-35

274. Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis. 2014, 73:1819-25

273. Landewé R, Strand V, van der Heijde D. From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials. Ann Rheum Dis. 2013 Jul;72(7):1113-7.

272. Smolen JS, van der Heijde DM, Keystone EC, van Vollenhoven RF, Goldring MB, Guérette B, Cifaldi MA, Chen N, Liu S, Landewé RB. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis. 2013 Jul;72(7):1156-62.

271. Machado P, Landewé R. Spondyloarthritis: Is it time to replace BASDAI with ASDAS? Nat Rev Rheumatol. 2013 Jul;9(7):388-90.

270. Schoels MM, Braun J, Dougados M, Emery P, Fitzgerald O, Kavanaugh A, Kvien TK, Landewé R, Luger

T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Sieper J, Smolen JS, Wit MD, van der Heijde D. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.
Ann Rheum Dis. 2014, 73:6-1

269. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Schoels M, Sieper J, Wit MD, Baraliakos X, Betteridge N, Burgos-Vargas R, Collantes-Estevez E, Deodhar A, Elewaut D, Gossec L, Jongkees M, Maccarone M, Redlich K, van den Bosch F, Wei JC, Winthrop K, van der Heijde D. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.
Ann Rheum Dis. 2014 73:6-16

268. Machado P, Landewé R, Braun J, Baraliakos X, Hermann KG, Hsu B, Baker D, van der Heijde D. Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype.
Ann Rheum Dis. 2013 Jun;72(6):1104-7.

267. Colebatch AN, Edwards CJ, Østergaard M, van der Heijde D, Balint PV, D'Agostino MA, Forslind K, Grassi W, Haavardsholm EA, Haugeberg G, Jurik AG, Landewé RB, Naredo E, O'Connor PJ, Ostendorf B, Potocki K, Schmidt WA, Smolen JS, Sokolovic S, Watt I, Conaghan PG. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis.
Ann Rheum Dis. 2013 Jun;72(6):804-14.

266. Navarro-Compán V, van der Heijde D, Ahmad HA, Miller CG, Wolterbeek R, Landewé R. Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC) revisited.
Ann Rheum Dis. 2014, 73:1067-70

265. Van der Heijde D, van der Helm-van Mil AH, Aletaha D, Bingham CO, Burmester GR, Dougados M, Emery P, Felson D, Knevel R, Kvien TK, Landewé RB, Lukas C, McInnes I, Silman AJ, Smolen JS, Stanislawska-Biernat E, Zink A, Combe B. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria.
Ann Rheum Dis. 2013 Apr;72(4):479-81.

264. Stolwijk C, Pierik M, Landewé R, Masclee A, van Tubergen A. Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease.
Can J Gastroenterol. 2013 Apr;27(4):199-205.

263. Landewé RB. Methotrexate saves lives: a pearl of observational research.
Arthritis Rheum. 2013 Feb;65(2):307-9.

262. Van Eijk-Hustings Y, Kroese M, Tan F, Boonen A, Bessems-Beks M, Landewé R. Challenges in demonstrating the effectiveness of multidisciplinary treatment on quality of life, participation and health care utilisation in patients with fibromyalgia: a randomised controlled trial.
Clin Rheumatol. 2013 Feb;32(2):199-209.

261. Ramiro S, van Tubergen A, Stolwijk C, Landewé R, van de Bosch F, Dougados M, van der Heijde D. Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Arthritis Res Ther. 2013 Jan 17;15(1):R14. [Epub ahead of print]

2012

260. Machado P, Landewé RB, Braun J, Baraliakos X, Hermann KG, Hsu B, Baker D, van der Heijde D. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.
Ann Rheum Dis. 2012 Dec;71(12):2002-5.

259. Kroon F, Landewé R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of

inflammation on radiographic progression in patients with ankylosing spondylitis.
Ann Rheum Dis. 2012 Oct;71(10):1623-9.

258. Smolen JS, Kay J, Landewé RB, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Zhou Y, Hsia EC, Doyle MK. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160.
Ann Rheum Dis. 2012 Oct;71(10):1671-9.

257. Radner H, Ramiro S, van der Heijde DM, Landewé R, Buchbinder R, Aletaha D. How do gastrointestinal or liver comorbidities influence the choice of pain treatment in inflammatory arthritis? A Cochrane systematic review.
J Rheumatol Suppl. 2012 Sep;90:74-80.

256. Ramiro S, Radner H, van der Heijde DM, Buchbinder R, Aletaha D, Landewé RB. Combination therapy for pain management in inflammatory arthritis: a Cochrane systematic review.
J Rheumatol Suppl. 2012 Sep;90:47-55.

255. Keystone EC, Combe B, Smolen J, Strand V, Goel N, van Vollenhoven R, Mease P, Landewé R, Fleischmann R, Luijckens K, van der Heijde D. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.
Rheumatology (Oxford). 2012 Sep;51(9):1628-38.

254. Hermann KG, Baraliakos X, van der Heijde DM, Jurik AG, Landewé R, Marzo-Ortega H, Østergaard M, Rudwaleit M, Sieper J, Braun J; Assessment in SpondyloArthritis international Society (ASAS). Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group.
Ann Rheum Dis. 2012 Aug;71(8):1278-88.

253. Van der Horst-Bruinsma IE, Nurmohamed MT, Landewé RB. Comorbidities in patients with spondyloarthritis.
Rheum Dis Clin North Am. 2012 Aug;38(3):523-38.

252. Van Tubergen A, van der Heijde D, Dougados M, Mielants H, Landewé R. Are syndesmophytes most prevalent in the lumbar or in the cervical spine in patients with ankylosing spondylitis and do they develop in a specific direction?
Rheumatology (Oxford). 2012 Aug;51(8):1432-9.

251. Whittle SL, Colebatch AN, Buchbinder R, Edwards CJ, Adams K, Englbrecht M, Hazlewood G, Marks JL, Radner H, Ramiro S, Richards BL, Turner IH, Aletaha D, Bombardier C, Landewé RB, Müller-Ladner U, Bijlsma JW, Branco JC, Bykerk VP, da Rocha Castelar Pinheiro G, Catrina AI, Hannonen P, Kiely P, Leeb B, Lie E, Martinez-Osuna P, Montecucco C, Ostergaard M, Westhovens R, Zochling J, van der Heijde D. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative.
Rheumatology (Oxford). 2012 Aug;51(8):1416-25.

250. Van der Heijde D, Keystone EC, Curtis JR, Landewé RB, Schiff MH, Khanna D, Kvien TK, Ionescu L, Gervitz LM, Davies OR, Luijckens K, Furst DE. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.
J Rheumatol. 2012 Jul;39(7):1326-33.

249. Van Tubergen A, Ramiro S, van der Heijde D, Dougados M, Mielants H, Landewé R. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study.
Ann Rheum Dis. 2012 Apr;71(4):518-23.

248. Van der Heijde D, Machado P, Braun J, Hermann KG, Baraliakos X, Hsu B, Baker D, Landewé R. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel

analysis in patients with ankylosing spondylitis.
Ann Rheum Dis. 2012 Mar;71(3):369-73.

247. Radner H, Ramiro S, Buchbinder R, [Landewé RB](#), van der Heijde D, Aletaha D. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritides) and gastrointestinal or liver comorbidity.
Cochrane Database Syst Rev. 2012 Jan 18;1:CD008951.

246. Van Eijk-Hustings Y, van Tubergen A, Boström C, Braychenko E, Buss B, Felix J, Firth J, Hammond A, Harston B, Hernandez C, Huzjak M, Korandová J, Kukkurainen ML, [Landewé R](#), Mezieres M, Milincovic M, Moretti A, Oliver S, Primdahl J, Scholte-Voshaar M, de la Torre-Aboki J, Waite-Jones J, Westhovens R, Zangi HA, Heiberg T, Hill J; EULAR. EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis.
Ann Rheum Dis. 2012 Jan;71(1):13-9..

245. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, [Landewé R](#), Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P; European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.
Ann Rheum Dis. 2012 Jan;71(1):4-12..

2011

244. Landewé R, van der Heijde D. Joint space narrowing, cartilage and physical function: are we deceived by measurements and distributions?
Ann Rheum Dis 2011; 70:717-8.

243. Lukas C, Combe B, Ravaud P, Sibilia J, [Landewé R](#), van der Heijde D. Favorable effect of very early DMARD treatment on radiographic progression in early inflammatory arthritis. The ESPOIR cohort study.
Arthritis Rheum 2011, 63:1804-11

242. Van Onna M, Jurik AG, van der Heijde D, van Tubergen A, Heuft-Dorenbosch L, [Landewé R](#). HLA-B27 and gender independently determine the likelihood of a positive MRI of the sacroiliac joints in patients with early inflammatory back pain: a 2-year MRI follow-up study.
Ann Rheum Dis. 2011 Nov;70(11):1981-5..

241. Ramiro S, Radner H, van der Heijde D, van Tubergen A, Buchbinder R, Aletaha D, [Landewé RB](#). Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
Cochrane Database Syst Rev. 2011 Oct 5;(10):CD008886.

240. Machado P, [Landewé R](#), Braun J, Hermann KG, Baraliakos X, Baker D, Hsu B, van der Heijde D. A stratified model for health outcomes in ankylosing spondylitis.
Ann Rheum Dis. 2011 Oct;70(10):1758-64.

[239. Landewé R](#), Gorter S, Gaujoux-Viala C, Gossec L, Smolen JS. On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: comment on the article by Graudal et al.
Arthritis Rheum. 2011 Oct;63(10):3182-4; discussion 3184-6.

238. Baraliakos X, van der Heijde D, Braun J, [Landewé RB](#). OMERACT magnetic resonance imaging initiative on structural and inflammatory lesions in ankylosing spondylitis--report of a special interest group at OMERACT 10 on sacroiliac joint and spine lesions.
J Rheumatol. 2011 Sep;38(9):2051-4.

237. [Landewé RB](#), Strand V, Conaghan PG, van der Heijde D. Damage and progression on radiographs in individual joints: data from pivotal randomized controlled trials.

J Rheumatol. 2011 Sep;38(9):2018-22.

236. Strand V, Kingsbury SR, Woodworth T, [Landewé R](#), Ostergaard M, Peterfy C, van der Heijde D, D'Agostino MA, Maksymowych W, Tak PP, Wells G, Conaghan PG. OMERACT 10 Sharp Symposium: important findings in examination of imaging methods for measurement of joint damage in rheumatoid arthritis.

J Rheumatol. 2011 Sep;38(9):2009-13.

235. Ramiro S, Roque R, Vinagre F, Cordeiro A, Tavares V, Van Tubergen A, Canas da Silva J, [Landewé R](#), Santos MJ. Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive? Acta Reumatol Port. 2011 Jul-Sep;36(3):234-42

234. Heldmann F, Brandt J, van der Horst-Bruinsma IE, [Landewé R](#), Sieper J, Burmester GR, van den Bosch F, de Vlam K, Geusens P, Gaston H, Schewe S, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Listing J, Braun J. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol. 2011 Jul-Aug;29(4):672-80.

233. Machado PM, [Landewé RB](#), van der Heijde DM. Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10. J Rheumatol. 2011 Jul;38(7):1502-6.

232. Kroese ME, Severens JL, Schulpen GJ, Bessems MC, Nijhuis FJ, [Landewé RB](#). Specialized rheumatology nurse substitutes for rheumatologists in the diagnostic process of fibromyalgia: a cost-consequence analysis and a randomized controlled trial.

J Rheumatol. 2011 Jul;38(7):1413-22.

231. Van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, [Landewé R](#), Rudwaleit M, Braun J; Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011 Jun;70(6):905-8. doi: 10.1136/ard.2011.151563.

230. Van der Heijde D, [Landewé RB](#). Dramatic repair of joint damage in psoriatic arthritis. J Rheumatol. 2011 Jun;38(6):969-70.

229. [Landewé R](#), van der Heijde D. Joint space narrowing, cartilage and physical function: are we deceived by measurements and distributions? Ann Rheum Dis. 2011 May;70(5):717-8.

228. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, [Landewé R](#), Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011 Mar;70(3):404-13.

227. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, [Landewé R](#), Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M; American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar;63(3):573-86.

226. Hazlewood G, Aletaha D, Carmona L, [Landewé RB](#), van der Heijde DM, Bijlsma JW, Bykerk VP, Canhão H, Catrina AI, Durez P, Edwards CJ, Leeb BF, Mjaavatten MD, Martinez-Osuna P, Montecucco C, Ostergaard

M, Serra-Bonett N, Xavier RM, Zochling J, Machado P, Thevissen K, Vercoutere W, Bombardier C. Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative. *J Rheumatol Suppl.* 2011 Mar;87:54-8.

225. Thevissen K, Vercoutere W, Bombardier C, [Landewé RB](#). Diagnostic and prognostic value of synovial biopsy in adult undifferentiated peripheral inflammatory arthritis: a systematic review. *J Rheumatol Suppl.* 2011 Mar;87:45-7..

224. Vercoutere W, Thevissen K, Bombardier C, [Landewé RB](#). Diagnostic and predictive value of acute-phase reactants in adult undifferentiated peripheral inflammatory arthritis: a systematic review. *J Rheumatol Suppl.* 2011 Mar;87:15-9..

223. Rudwaleit M, van der Heijde D, [Landewé R](#), Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, Van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Weber U, Wei J, Sieper J. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis.* 2011 Jan;70(1):25-31..

222. Machado P, [Landewé R](#), Lie E, Kvien TK, Braun J, Baker D, van der Heijde D; Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. *Ann Rheum Dis.* 2011 Jan;70(1):47-53..

221. Machado P, Castrejon I, Katchamart W, Koevoets R, Kuriya B, Schoels M, Silva-Fernández L, Thevissen K, Vercoutere W, Villeneuve E, Aletaha D, Carmona L, [Landewé R](#), van der Heijde D, Bijlsma JW, Bykerk V, Canhão H, Catrina AI, Durez P, Edwards CJ, Mjaavatten MD, Leeb BF, Losada B, Martín-Mola EM, Martínez-Osuna P, Montecucco C, Müller-Ladner U, Østergaard M, Sheane B, Xavier RM, Zochling J, Bombardier C. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Ann Rheum Dis.* 2011 Jan;70(1):15-24.

220. [Landewé RB](#), van der Heijde DM. [The recognition of patients with spondyloarthritis. New classification criteria]. *Ned Tijdschr Geneesk.* 2011;155(30-31):A3680.

219. Bijlsma JW, Hagemeyer JW, Bijl M, Jansen TL, van de Laar MA, [Landewé RB](#), Nurmohamed MT. [The multidisciplinary practice guideline "The responsible use of biologicals"]. *Ned Tijdschr Geneesk.* 2011;155(30-31):A3114.

218. Machado P, [Landewé R](#), Lie E, Kvien TK, Braun J, Baker D, van der Heijde D. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.; for the Assessment of SpondyloArthritis international Society. *Ann Rheum Dis.* 2011 Jan;70(1)47-53.

217. Machado P, Castrejon I, Katchamart W, Koevoets R, Kuriya B, Schoels M, Silva-Fernández L, Thevissen K, Vercoutere W, Villeneuve E, Aletaha D, Carmona L, [Landewé R](#), van der Heijde D, Bijlsma JW, Bykerk V, Canhão H, Catrina AI, Durez P, Edwards CJ, Mjaavatten MD, Leeb BF, Losada B, Martín-Mola EM, Martínez-Osuna P, Montecucco C, Müller-Ladner U, Ostergaard M, Sheane B, Xavier RM, Zochling J, Bombardier C. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Ann Rheum Dis.* 2011 Jan;70(1)15-24.

2010

216. Machado P, [Landewé R](#), Lie E, Kvien TK, Braun J, Baker D, van der Heijde D. [Ankylosing Spondylitis Disease Activity Score \(ASDAS\): defining cut-off values for disease activity states and improvement](#)

[scores](#); for the Assessment of SpondyloArthritis international Society.
Ann Rheum Dis. 2010;70:47-53

215. Ramiro S, Machado P, Singh JA, Landewé RB, da Silva JA. [Applying science in practice: the optimization of biological therapy in rheumatoid arthritis](#).
Arthritis Res Ther. 2010;12(6):220.

214. van der Heijde D, Rudwaleit M, Landewé RB, Sieper J. [Justification for including MRI as a tool in the diagnosis of axial SpA](#).
Nat Rev Rheumatol. 2010;6:670-2.

213. van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
J Rheumatol. 2010;37:2237-46.

212. Ramiro S, van Tubergen AM, Landewé RB. [RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis](#).
Expert Rev Clin Immunol. 2010;6:713-20.

211. Machado P, Castrejon I, Katchamart W, Koevoets R, Kuriya B, Schoels M, Silva-Fernández L, Thevissen K, Vercoutere W, Villeneuve E, Aletaha D, Carmona L, Landewé R, van der Heijde D, Bijlsma JW, Bykerk V, Canhão H, Catrina AI, Durez P, Edwards CJ, Mjaavatten MD, Leeb BF, Losada B, Martín-Mola EM, Martínez-Osuna P, Montecucco C, Müller-Ladner U, Ostergaard M, Sheane B, Xavier RM, Zochling J, Bombardier C. [Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative](#).
Ann Rheum Dis. 2010;70:15-24

210. Landewé RB. [Efficacy assessed in follow-ups of clinical trials: methodological conundrum](#).
Arthritis Res Ther. 2010;12:132.

209. Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landewé RB, Brandenburg VM, Bekers O, Vermeer C. [Characterisation and potential diagnostic value of circulating matrix Gla protein \(MGP\) species](#).
Thromb Haemost. 2010;104:811-22.

208. Bours MJ, Peeters RH, Landewé RB, Beijer S, Arts IC, Dagnelie PC. [Adenosine 5'-triphosphate infusions reduced disease activity and inflammation in a patient with active rheumatoid arthritis](#).
Rheumatology (Oxford). 2010;49:2223-5.

207. Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewé R, Listing J, Nicola PJ, Tarp U, Zink A, Askling J. [EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology](#).
Ann Rheum Dis. 2010;69:1596-602.

206. van Tuyl LH, Voskuyl AE, Boers M, Geusens P, Landewé RB, Dijkmans BA, Lems WF. [Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis](#).
Ann Rheum Dis. 2010;69:1623-8.

205. Dougados M, Combe B, Braun J, Landewé R, Sibia J, Cantagrel A, Feydy A, van der Heijde D, Leblanc V, Logeart I. [A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial](#).
Ann Rheum Dis. 2010;69:1430-5.

204. Ten Cate DF, Luime JJ, Hazes JM, Jacobs JW, Landewé R. [Does the intraclass correlation coefficient always reliably express reliability? Comment on the article by Cheung et al](#).
Arthritis Care Res (Hoboken). 2010;62:1357-8

203. Machado P, [Landewé R](#), Braun J, Hermann KG, Baker D, van der Heijde D. [Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis.](#)
Ann Rheum Dis. 2010;69:1465-70.
202. Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, [Landewé R](#). [Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.](#)
Ann Rheum Dis. 2010;69:1010-4.
201. Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B, [Landewé RB](#), Smolen JS, Sokka T, van der Heijde DM. [Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.](#)
Ann Rheum Dis. 2010;69:987-94.
200. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, [Landewé R](#), Smolen JS, Emery P, Buch MH. [Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.](#)
Ann Rheum Dis. 2010;69:976-86.
199. Gaujoux-Viala C, Smolen JS, [Landewé R](#), Dougados M, Kvien TK, Mola EM, Scholte-Voshaar M, van Riel P, Gossec L. [Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.](#)
Ann Rheum Dis. 2010;69:1004-9.
198. Schoels M, Wong J, Scott DL, Zink A, Richards P, [Landewé R](#), Smolen JS, Aletaha D. [Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.](#)
Ann Rheum Dis. 2010;69:995-1003.
197. Smolen JS, [Landewé R](#), Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D. [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.](#)
Ann Rheum Dis. 2010;69:964-75.
196. Boonen A, Brinkhuizen T, [Landewé R](#), van der Heijde D, Severens JL. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost.
Ann Rheum Dis. 2010;69:1123-8.
195. Machold KP, [Landewé R](#), Smolen JS, Stamm TA, van der Heijde DM, Verpoort KN, Brickmann K, Vázquez-Mellado J, Karateev DE, Breedveld FC, Emery P, Huizinga TW. The stop arthritis very early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.
Ann Rheum Dis. 2010;69:495-502.
194. [Landewé RB](#). Magnetic Resonance imaging in the diagnosis of ankylosing spondylitis: be aware of gold standards and circularity.
J Rheumatol 2010;37:477-8.
193. Gladman DD, [Landewé R](#), McHugh NJ, Fitzgerald O, Thaci D, Coates L, Mease PJ, Qureshi AA, Krueger GG, Ritchlin CT, Kavanaugh AF, Garg A. Composite measures in psoriatic arthritis: GRAPPA 2008.
J Rheumatol. 2010;37:453-61.

2009

192. [Landewé R](#), van der Heijde D. A Systematic comparison of rheumatoid arthritis and ankylosing spondylitis: structural outcomes. Clin Exp Rheumatol. 2009;27 (suppl 55): S102-7.
191. Lukas C, van der Heijde D, Fatenejad S, [Landewé R](#). [Repair of erosions occurs almost exclusively in damaged joints without swelling](#). Ann Rheum Dis. 2010;69:851-5.
190. van Tubergen AM, [Landewé RB](#). [Tools for monitoring spondyloarthritis in clinical practice](#). Nat Rev Rheumatol. 2009;5:608-15.
189. [Landewé RB](#), Houbiers JG, Van den Bosch FE, In 't Hout J, Verschueren PC, Meijerink JH, van den Hoogen FH, Masek BA, Bruyn GA, Wouters JM, Voskuyl AE, van Laar JM, Bijlsma JJ, Breedveld FC, van de Putte LB, Miltenburg AM, De Keyser F. [Intranasal administration of recombinant Human Cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: A Phase II, multicenter, double-blind, randomized, placebo-controlled, parallel group dose-finding trial](#). Ann Rheum Dis. 2010;69:1655-9.
188. [Landewé RB](#), van Tubergen A. [Clinical assessment and outcome research in spondyloarthritis](#). Curr Rheumatol Rep. 2009;11: 334-9.
187. van der Heijde D, Salonen D, Weissman BN, [Landewé R](#), Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R; Canadian (M03-606) study group; ATLAS study group. [Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years](#). Arthritis Res Ther. 2009;11:R127.
186. Maksymowych WP, Fitzgerald O, Wells GA, Gladman DD, [Landewé R](#), Ostergaard M, Taylor WJ, Christensen R, Tak PP, Boers M, Syversen SW, Bathon JM, Ritchlin CJ, Mease PJ, Bykerk VP, Garnero P, Geusens P, El-Gabalawy H, Aletaha D, Inman RD, Kraus VB, Kvien TK. [Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design](#). J Rheumatol. 2009;36:1792-9.
185. Maksymowych WP, [Landewé R](#), Tak PP, Ritchlin CJ, Ostergaard M, Mease PJ, El-Gabalawy H, Garnero P, Gladman DD, Fitzgerald O, Aletaha D, Bykerk VP, Bathon JM, Syversen SW, Boers M, Geusens P, Inman RD, Kraus VB, Kvien TK, Taylor WJ, Wells GA. [Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria](#). J Rheumatol. 2009;36:1785-91.
184. Sharp JT, Angwin J, Boers M, Duryea J, Finckh A, Hall JR, Kauffman JA, [Landewé R](#), Langs G, Lukas C, Moens HJ, Peloschek P, Strand CV. [Multiple computer-based methods of measuring joint space width can discriminate between treatment arms in the COBRA trial -- Update of an ongoing OMERACT project](#). J Rheumatol. 2009;36:1825-8
183. Syversen SW, [Landewé R](#), van der Heijde D, Bathon JM, Boers M, Bykerk VP, Fitzgerald O, Gladman DD, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus V, Kvien TK, Mease PJ, Ostergaard M, Ritchlin CJ, Tak PP, Taylor WJ, Maksymowych WP. Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers. J Rheumatol 2009; 36: 1769-84
182. Smolen JS, Kay J, Doyle MK, [Landewé R](#), Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; for the GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Lancet. 2009; 374: 210-21.

181. Sieper J, van der Heijde D, Landewé R, Brandt J, Burgos-Vagas R, Collantes-Estevez E, Dijkmans B, Dougados M, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Rudwaleit M. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS).
Ann Rheum Dis. 2009;68:784-8

180. Landewé RB, Günther K, Lukas C, Braun J, Combe B, Conaghan PG, Dreinhöfer K, Fritschy D, Getty J, van der Heide HJ, Kvien TK, Machold K, Mihai C, Mosconi M, Nelissen R, Pascual E, Pavelka K, Pileckyte M, Puhl W, Punzi L, Rütther W, San-Julian M, Tudisco C, Westhovens R, Witso E, van der Heijde DM. EULAR/EFFORT. Recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee.
Ann Rheum Dis. 2009; 69:12-9

179. Syversen SW, Goll GL, van der Heijde D, Landewé RB, Lie BA, Odegård S, Uhlig, T, Gaarder PI, Kvien TK. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a ten-year prospective study.
Ann Rheum Dis. 2010;69:345-51.

178. Syversen SW, Goll GL, van der Heijde D, Landewé R, Gaarder PI, Odegård S, Haavardsholm EA, Kvien TK. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression.
J Rheumatol. 2009;36:266-72.

177. Hoff M, Haugeberg G, Odegård S, Syversen S, Landewé R, van der Heijde D, Kvien TK. Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up.
Ann Rheum Dis. 2009;68:324-9.

176. Hafström I, Albertsson K, Boonen A, van der Heijde D, Landewé R, Svensson B; BARFOT Study Group. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study.
Ann Rheum Dis. 2009;68:508-13.

175. Avouac J, Kowal-Bielecka O, Landewé R, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Földvari I, Furst DE, Müller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M; EUSTAR Coauthors. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research.
Ann Rheum Dis. 2009;68:629-34.

174. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Földvari I, Furst DE, Müller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M; EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
Ann Rheum Dis. 2009;68:620-8.

173. Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine.
Ann Rheum Dis. 2009;68:863-7.

172. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijckens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D. Efficacy and safety of certolizumab pegol

plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Ann Rheum Dis.* 2009;68:797-804.

171. Rudwaleit M, van der Heijde D, [Landewé R](#), Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis.* 2009;68:777-83.

170. Rudwaleit M, [Landewé R](#), van der Heijde D, Listing J, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinsma IE, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Sturrock R, de Vlam K, Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Ann Rheum Dis.* 2009;68:770-6.

169. Lukas C, Guillemin F, [Landewé R](#), van der Heijde D, Logeart I, Fautrel B, Daures JP, Combe B; ESPOIR cohort. Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study. [Clin Exp Rheumatol.](#) 2009;27:84-91.

168. Kroese M, Schulpen G, Bessems M, Nijhuis F, Severens J, [Landewé R](#). The feasibility and efficacy of a multidisciplinary intervention with aftercare meetings for fibromyalgia. *Clin Rheumatol.* 2009; 28: 923-9

167. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, [Landewé R](#), Maksymowych W, van der Heijde D. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. *Ann Rheum Dis.* 2009;68 suppl 2:ii1-44.

166. van Tuyl LH, Boers M, Lems WF, [Landewé RB](#), Han H, van der Linden S, van der Laar MA, Westhovens R, Van Denderen JC, Westedt ML, Peeters AJ, Jacobs P, Huizinga TW, van den Brink H, Dijkmans BA, Voskuyl AE. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. *Ann Rheum Dis.* 2010 May;69:807-12.

165. [Rudwaleit M](#), [Jurik AG](#), [Hermann KG](#), [Landewé R](#), [van der Heijde D](#), [Baraliakos X](#), [Marzo-Ortega H](#), [Ostergaard M](#), [Braun J](#), [Sieper J](#). Defining active sacroiliitis on Magnetic Resonance Imaging (MRI) for classification of axial spondyloarthritis - a consensual approach by the ASAS/ OMERACT MRI Group. *Ann Rheum Dis* 2009; 68:1520-7

164. [Landewé RB](#). American College of Rheumatology recommendations for the treatment of RA an issue of choices. *Nat Clin Pract Rheumatol.* 2009;5:8-9.

163. Lukas C, [Landewé R](#), Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis.* 2009;68:18-24.

2008

162. Lukas C, [Landewé RB](#), Fatenejad S, van der Heijde DM. Subtle changes in individual joints result in both positive and negative change scores in a patient: Results from a clinical trial in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2009 Nov;68:1691-5.

161. Keystone E, Heijde DV, Mason D Jr, [Landewé R](#), Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K. Certolizumab pegol plus methotrexate is significantly more effective than placebo

plus methotrexate in active rheumatoid arthritis. Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum.* 2008;58:3319-29.

160. van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. *Arthritis Rheum.* 2008;58:3063-70.

159. Lukas C, Sharp JT, Angwin J, Boers M, Duryea J, Hall JR, et al. Automated measurement of joint space width in small joints of patients with rheumatoid arthritis. *J Rheumatol.* 2008;35:1288-93.

158. Aletaha D, Landewé R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. *Ann Rheum Dis.* 2008;67:1360-4.

157. Karonitsch, T, Aletaha, D, Boers, M, Bombardieri, S, Combe, B, Dougados, M, Emery, P, Felson, D, Gomez-Reino, J, Keystone, E, Kvien, T K, Martin-Mola, E, Matucci-Cerinic, M, Richards, P, van Riel, P, Siegel, J, Smolen, J S, Sokka, T, van der Heijde, D, van Vollenhoven, R, Ward, M, Wells, G, Zink, A, Landewé, R. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis. *Ann Rheum Dis.* 2008;67:1365-1373.

156. Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. *Ann Rheum Dis.* 2008;68:863-7.

155. Kroese ME, Schulpen GJ, Bessems MC, Severens JL, Nijhuis FJ, Geusens PP, et al. Substitution of specialized rheumatology nurses for rheumatologists in the diagnostic process of fibromyalgia: A randomized controlled trial. *Arthritis Rheum.* 2008 15;59:1299-305.

154. Hoff M, Haugeberg G, Odegard S, Syversen SW, Landewé R, van der Heijde D, et al. Cortical hand bone loss after one year in early rheumatoid arthritis predicts radiographic hand joint damage at 5 and 10 year follow-up. *Ann Rheum Dis.* 2008;68:324-9.

153. Halvorsen EH, Pollmann S, Gilboe IM, van der Heijde D, Landewé R, Odegard S, et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. *Ann Rheum Dis.* 2008;67:414-7.

152. Hafstrom I, Albertsson K, Boonen A, van der Heijde DM, Landewé R, Svensson B. Remission achieved after 2 years treatment with low dose prednisolone in addition to DMARDs in early RA is associated with reduced joint destruction still present after 4 years: an open two year continuation study. *Ann Rheum Dis.* 2008;68:508-13.

151. Dias EM, Lukas C, Landewé R, Fatenejad S, van der Heijde D. Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp-van der Heijde method for scoring radiographs in rheumatoid arthritis. *Ann Rheum Dis.* 2008;67:375-9.

150. van der Heijde D, [Landewé R](#), Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. *Ann Rheum Dis*. 2008;67:489-93.

149. van der Heijde D, [Landewé R](#), Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. *Arthritis Rheum*. 2008;58:1324-31.

148. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. *Ann Rheum Dis*. 2008;67:212-7.

147. Vosse D, [Landewé R](#), Garnero P, van der Heijde D, van der Linden S, Geusens P. Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. *Rheumatology (Oxford)*. 2008;47:1219-22.

146. van der Heijde D, [Landewé R](#), van Vollenhoven R, Fatenejad S, Klareskog L. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. *Ann Rheum Dis*. 2008;67:1267-70.

2007

145. Vosse D, Heijckmann C, [Landewé R](#), van der Heijde D, van der Linden S, Geusens P. Comparing morphometric X-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. *Rheumatology (Oxford)*. 2007;46:1667-71.

144. van der Heijde D, [Landewé R](#), Hermann KG, Rudwaleit M, Ostergaard M, Oostveen A, et al. Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? *J Rheumatol*. 2007;34:871-3.

143. van der Heijde D, [Landewé R](#), Boonen A, Einstein S, Herborn G, Rau R, et al. Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis. *Arthritis Res Ther*. 2007;9:R62.

142. van der Heijde D, Klareskog L, [Landewé R](#), Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum*. 2007;56:3928-39.

141. Schett G, [Landewé R](#), van der Heijde D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? *Ann Rheum Dis*. 2007;66:709-11.

140. Maksymowych WP, [Landewé R](#), Conner-Spady B, Dougados M, Mielants H, van der Tempel H, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. *Arthritis Rheum*. 2007;56:1846-53.

139. Maksymowych WP, [Landewé R](#), Boers M, Garnero P, Geusens P, El-Gabalawy H, et al. Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. *J Rheumatol*. 2007;34:634-40.

138. Lie BA, Viken MK, Odegard S, van der Heijde D, Landewé R, Uhlig T, et al. Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study. *Ann Rheum Dis*. 2007;66:1604-9.
137. Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. *J Rheumatol*. 2007;34:607-15.
136. Landewé R, van der Heijde D. Primer: challenges in randomized and observational studies. *Nat Clin Pract Rheumatol*. 2007;3:661-6.
135. Landewé R. Predictive markers in rapidly progressing rheumatoid arthritis. *J Rheumatol*. 2007;80 (Suppl):8-15.
134. Keeling SO, Landewé R, van der Heijde D, Bathon J, Boers M, Garnero P, et al. Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. *J Rheumatol*. 2007;34:623-33.
133. Hammer HB, Odegard S, Fagerhol MK, Landewé R, van der Heijde D, Uhlig T, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. *Ann Rheum Dis*. 2007;66:1093-7.
132. Gladman DD, Inman RD, Cook RJ, van der Heijde D, Landewé RB, Braun J, et al. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. *J Rheumatol*. 2007;34:1733-9.
131. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, et al. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. *J Rheumatol*. 2007;34:1740-5.
130. Boonen A, van der Heijde D, Landewé R, van Tubergen A, Mielants H, Dougados M, et al. How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? *Ann Rheum Dis*. 2007;66:771-7.
129. Heuft-Dorenbosch L, Weijers R, Landewé R, van der Linden S, van der Heijde D. Magnetic resonance imaging changes of sacroiliac joints in patients with recent-onset inflammatory back pain: inter-reader reliability and prevalence of abnormalities. *Arthritis Res Ther*. 2006;8:R11.
128. Combe B, Landewé R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola E, Nielsen H, Silman A, Smolen J, Yazici H. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis*. 2007;66:34-45.
127. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heijde D, Landewé R, Lacey D, Richards WG, Schett G. Dickkopf-1 is a master regulator of joint remodeling. *Nat Med*. 2007;13:156-63.
126. Keeling SO, Landewé R, van der Heijde D, Bathon J, Boers M, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus VB, Kvien TK, Mease PJ, Ostergaard M, Ritchlin C, Syversen SW, Maksymowych WP. Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting

structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. *J Rheumatol.* 2007;34:623-33.

125. Maksymowych WP, [Landewé R](#), Boers M, Garnero P, Geusens P, El-Gabalawy H, Heinegard D, Krause V, Lohmander S, Matyas J, Saxne T, van der Heijde D. Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. *J Rheumatol.* 2007;34:634-40.

124. Lukas C, Braun J, van der Heijde D, Hermann KG, Rudwaleit M, Ostergaard M, Oostveen A, O'Connor P, Maksymowych WP, Lambert RG, Jurik AG, Baraliakos X, [Landewé R](#); ASAS/OMERACT MRI in AS Working Group. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. *J Rheumatol.* 2007;34:862-70.

123. van der Heijde D, [Landewé R](#), Hermann KG, Rudwaleit M, Ostergaard M, Oostveen A, O'Connor P, Maksymowych WP, Lambert RG, Lukas C, Jurik AG, Boers M, Baraliakos X, Braun J; ASAS/OMERACT MRI in AS Working Group. Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? *J Rheumatol.* 2007;34:871-3.

122. Sharp JT, Angwin J, Boers M, Duryea J, von Ingersleben G, Hall JR, Kauffman JA, [Landewé R](#), Langs G, Lukas C, Maillefert JF, Bernelot Moens HJ, Peloschek P, Strand V, van der Heijde D. Computer based methods for measurement of joint space width: update of an ongoing OMERACT project. *J Rheumatol.* 2007;34:874-83.

121. van der Heijde D, [Landewé R](#), Sharp JT; OMERACT Subcommittee on Repair. Repair in rheumatoid arthritis, current status. Report of a workshop at OMERACT 8. *J Rheumatol.* 2007;34:884-8.

120. Heuft-Dorenbosch L, [Landewé R](#), Weijers R, Houben H, van der Linden S, Jacobs P, van der Heijde D. Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic. *Ann Rheum Dis.* 2007;66:92-98.

2006

119. Maksymowych WP, [Landewé R](#), BM. Imaging in Ankylosing Spondylitis. *Best Pract Res Clin Rheumatol.* 2006;20:507-19.

118. [Landewé R](#), van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. *Arthritis Rheum.* 2006;54:3119-25.

117. Vosse D, van der Heijde D, [Landewé R](#), Geusens P, Mielants H, Dougados M, van der Linden S. Determinants of hyperkyphosis in patients with ankylosing spondylitis. *Ann Rheum Dis.* 2006;65:770-774.

116. Braun J, [Landewé R](#), Hermann K-G, Han J, Yan S, Williamson P, van der Heijde D for the ASSERT Study Group. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. *Arthritis Rheum.* 2006;54:1646-1652.

115. Geusens P, [Landewé R](#), Garnero P, Chen D, Dunstan D, Lems W, Stinissen P, van der Heijde D, van der Linden S, Boers. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. *Arthritis Rheum.* 2006;54:1772-1777.

114. Landewé R, van der Heijde D. The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. *Arthritis Research & Therapy*. 2006;8:107.

113. Landewé R, van der Heijde D, van der Linden S, Boers M. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. *Ann Rheum Dis*. 2006;65:637-641.

112. Heuft-Dorenbosch L, Landewé R, Weijers R, Wanders A, Houben H, van der Linden S, van der Heijde D. Combining information obtained from MRI and conventional radiographs in order to detect sacroiliitis in patients with recent-onset inflammatory back pain. *Ann Rheum Dis*. 2006;65:804-808.

111. Ødegård S, Landewé R, van der Heijde D, Kvien T, Mowinckel P, Uhlig T. Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. *Arthritis Rheum*. 2006;54:68-75.

110. Pham T, Landewé R, van der Linden S, M Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, R Burgos-Vargas R, Edmonds J, I Olivieri I, van der Horst-Bruinsma I, Mielants H, Stone M, Emery P, van der Heijde D. An International Study on Starting TNF-blocking agents in Ankylosing Spondylitis (ISSAS). *Ann Rheum Dis*. 2006;65:1620-25.

109. Boonen A, van der Heijde D, Severens J, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, van der Linden S. Markov model into the cost-utility over five years of etanercept and infliximab compared to usual care in patients with active ankylosing spondylitis. *Ann Rheum Dis*. 2006;65:201-8.

108. Landewé R, Geusens P, van der Heijde D, Boers M, van der Linden S, Garnero P. Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis. *Ann Rheum Dis*. 2006;65:40-4.

107. Heuft-Dorenbosch L, Weijers R, Landewé R, van der Linden S, van der Heijde D. Magnetic Resonance Imaging changes of sacroiliac joints in patients with recent-onset inflammatory back pain: inter-reader reliability and prevalence of abnormalities. *Arthritis Res Therapy*. 2006;8:R11.

106. Spoorenberg A, van Tubergen A, Landewé R, Dougados M, van der Linden S, Mielants H, van der Tempel H, van der Heijde D. Krankheitsaktivität beim Morbus Bechterew aus Sicht des Arztes und aus Patientensicht. *Morbus-Bechterew-Journal*. 2006;105:pp4-6

2005

105. Wells G, Boers M, Shea B, Brooks P, Simon L, Strand V, Aletaha D, Anderson J, Bombardier C, Dougados M, Emery P, Felson D, Fransen J, Furst D, Hazes M, Johnson K, Kirwan J, Landewé R, Lassere M, Michaud K, Suarez-Amalzor M, Silman A, Smolen J, van der Heijde D, van Riel P, Wolfe F, Tugwell P. Low Disease Activity State for Rheumatoid Arthritis: A Preliminary Definition. *J Rheumatol*. 2005;32:2016-24.

104. Spoorenberg A, van Tubergen A, Landewé R, Dougados M, van der Linden S, Mielants H, van der Tempel H, van der Heijde D. Measuring Disease activity in Ankylosing Spondylitis: patients and physician have different perspectives. *Rheumatology*. 2005;44:789-95.

103. Wanders A, van der Heijde D, Landewé R, Béhier J-M, Calin A, Olivieri I, Zeidler H, Dougados M. Non-steroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing

spondylitis: a randomised clinical trial.
Arthritis Rheum. 2005;52:1756-65.

102. van der Heijde D, Landewé R. Imaging in spondylitis.
Curr Opin Rheumatol. 2005;17:413-7.

101. Gossec L, Landewé RB, Maillefert JF, Dougados M: OMERACT 7 Special Interest Group. Concomitant therapies as an outcome measure. Part 1: Drugs.
J Rheumatol. 2005;32:2447-8.

100. Huizinga TW, Landewé RB. Early aggressive therapy in rheumatoid arthritis: a “window of opportunity”?
Nat Clin Pract Rheumatol. 2005;1:2-3.

99. Wanders A, Landewé RBM, Dougados M, Mielants H, van der Linden S, van der Heijde D: The association between radiographic damage of the spine and spinal mobility for individual patients with Ankylosing Spondylitis: Can the assessment of spinal mobility be a proxy for radiographic evaluation?
Ann Rheum Dis. 2005;64:988-94.

98. van der Heijde D, Landewé R, Hermann K-G, Jurik A-G, Maksymowych W, Rudwaleit M, O'Connor P, Braun J and the ASAS/OMERACT MRI in AS working group. Application of the OMERACT filter to scoring methods for MRI of the SI joints and the spine. Recommendations for a research agenda at OMERACT.
J Rheumatol. 2005;32:2042-47.

97. Hermann K-GA, Landewé RBM, Braun J, van der Heijde DMFM. Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: Is paramagnetic contrast medium necessary?
J Rheumatol. 2005;32:2056-60.

96. Landewé R, Hermann K-G, van der Heijde D, Baraliakos X, Jurik A-G, Lambert R, Østergaard M, Rudwaleit M, Salonen D, Braun J and the ASAS/OMERACT MRI in AS working group. Scoring sacro-iliac joints by magnetic resonance imaging. A multiple-reader reliability experiment.
J Rheumatol. 2005;32:2050-5.

95. Hermann K-GA, Landewé RBM, Braun J, van der Heijde DMFM. Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: Is paramagnetic contrast medium necessary?
J Rheumatol. 2005;32:2056-60.

94. Landewé R, Hermann K-G, van der Heijde D, Baraliakos X, Jurik A-G, Lambert R, Østergaard M, Rudwaleit M, Salonen D, Braun J and the ASAS/OMERACT MRI in AS working group. Scoring sacro-iliac joints by magnetic resonance imaging, a multiple-reader reliability experiment.
J Rheumatol. 2005;32:2050-5.

93. van der Heijde D, Landewé R, and the ASAS working group. Selection of a method for scoring radiographs for AS clinical trials by ASAS and OMERACT.
J. Reumatol. 2005;2048-49.

92. van der Heijde D, Landewé R, Hermann K-G, Jurik A-G, Maksymowych W, Rudwaleit M, O'Connor P, Braun J and the ASAS/OMERACT MRI in AS working group. Application of the OMERACT filter to scoring methods for MRI of the SI joints and the spine. Recommendations for a research agenda at OMERACT 7.
J Rheumatol. 2005;32:2042-7.

91. Landewé R, van der Heijde D. Radiographic progression in rheumatoid arthritis.
Clin Exp Rheum. 2005;23(suppl 39):S63-S68.

90. Boonen A, Severens JL, van Tubergen A, Landewé R, Bonsel G, van der Heijde D, van der Linden SJ. Willingness of patients with ankylosing spondylitis to pay for inpatient treatment is influenced by the treatment environment and expectations of improvement.

Ann Rheum Dis. 2005;64:1650-52.

89. Landewé R, van der Heijde D. Presentation and analysis of radiographic data in clinical trials and observational studies.

Ann Rheum Dis. 2005;64 suppl IV:i48-51.

88. van der Heijde D, Landewé R, van der Linden S. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?

Arthritis Rheum. 2005;52:1979-85.

87. Wells G, Boers M, Shea B, Brooks P, Simon L, Strand V, Aletaha D, Anderson J, Bombardier C, Dougados M, Emery P, Felson D, Franssen J, Furst D, Hazes M, Johnson K, Kirwan J, Landewé R, Lassere M, Michaud K, Suarez-Amalzor M, Silman A, Smolen J, van der Heijde D, van Riel P, Wolfe F, Tugwell P. Minimal Disease Activity for Rheumatoid Arthritis: A Preliminary Definition.

J Rheum. 2005;32:2016-24.

86. Baraliakos X, Hermann K-G, Landewé R, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging (MRI): a comparison between contrast enhanced T1 and short-tau inversion recovery (STIR) sequences.

Ann Rheum Dis. 2005;64:1141-1144.

85. Baraliakos X, Landewé R, Hermann K-G, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. Inflammation in ankylosing spondylitis – a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging (MRI).

Ann Rheum Dis. 2005;64:730-4.

84. van der Heijde D, Klareskog L, Boers M, Landewé R, Codreanu C, Bolosiu H, Pedersen R, and Fatenejad S for the TEMPO investigators. Comparison of different definitions to classify remission and sustained remission: one year TEMPO results.

Ann Rheum Dis. 2005;64:1582-1587.

83. Spoorenberg A, van Tubergen A, Landewé R, Dougados M, van der Linden S, Mielants H, van der Tempel H, van der Heijde D. Measuring Disease activity in Ankylosing Spondylitis (AS): Patients and physicians have different perspectives.

Rheumatology (Oxford). 2005;44:789-95.

82. Wanders A, van der Heijde D, Landewé R, Behier JM, Calin A, Olivieri I, Zeidler H, Dougados M. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial.

Arthritis Rheum. 2005;52:1756-1765.

81. Wanders A, Landewé R, Dougados M, Mielants H, van der Linden S, van der Heijde D. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?

Ann Rheum Dis. 2005;64 988-994.

80. van der Heijde D, Landewé R, Klareskog L, Rodríguez-Valverde V, Settas L, Pedersen R, Fatenejad S. Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study.

Arthritis Rheum. 2005;52:49-60.

79. van der Heijde D, Braun J, Landewé R, Davis J, Sieper J, van der Linden S, Dougados M. ASsessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis?

Ann Rheum Dis. 2005;64 Suppl 2:ii108-9.

78. Boonen A, Landewé R. Health status in rheumatoid arthritis over 7 years.

Ann Rheum Dis. 2005; 64:173-5.

77. van der Heijde D, Braun J, Landewé R, Davis J, Sieper J, van der Linden S, Dougados M. Assessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis? *Ann Rheum Dis*. 2005, 64 (suppl 2):108-9.

76. Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, Landewé R, Steinfield SD, Emery P, Dijkmans BAC, Veale DJ: A randomised, double-blind, placebo controlled, multi- centre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. *Ann Rheum Dis*. 2005;64:859-64.

75. Baraliakos X, Landewé R, Herman K-G, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. : Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging (MRI): a comparison between contrast enhanced T1 and short-tau inversion recovery (STIR) sequences. *Ann Rheum Dis*. 2005;64:1141-4.

74. van der Heijde D, Landewé R, Klareskog L, Rodriguez-Valverde V, Settas L, Pedersen R, Fatenejad S.: Presentation and analysis of radiographic outcome in clinical trials: experience from the TEMPO trial. *Arthritis Rheum*. 2005;52:49-60.

73. Baraliakos X, Landewé R, Herman K-G, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J: Inflammation in ankylosing spondylitis – a systemic description of the extent and frequency of acute spinal changes using magnetic resonance imaging (MRI). *Ann Rheum Dis*. 2005;64:730-4

2004

72. Heuft-Dorenbosch L, Vosse D, Landewé R, Spoorenberg A, Dougados M, Mielants H, van der Tempel H, van der Linden S, van der Heijde D. Measurement of spinal mobility in ankylosing spondylitis: comparison of Occiput-to-Wall and Tragus-to-Wall distance. *J Rheum*. 2004;31:1779-84.

71. Boonen A, van der Heijde D, Landewé R, Chorus A, van Lankveld W, Miedema H, van der Tempel H, van der Linden S: Is avoidant coping independent of disease status and stable over time in patients with ankylosing spondylitis? *Ann Rheum Dis*. 2004;63:1264-8.

70. Wanders AJ, Gorman JD, Davis JC, Landewé RB, van der Heijde DM. Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. *Arthritis Rheum*. 2004;51:1-8.

69. Landewé R, van der Heijde D. Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. *Arthritis Rheum*. 2004;50:699-706.

68. Bruynesteyn K, Landewé R, Van Der Linden S, Van Der Heijde D. Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months follow- up. *Ann Rheum Dis*. 2004;63:1413-1418.

67. Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. *Arthritis Rheum*. 2004;51:154-9.

66. Landewé R, Rump B, van der Heijde D, van der Linden S. Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists. *Ann Rheum Dis*. 2004;63:530-4.

65. Landewé R, Geusens P, Boers M, van der Heijde D, Lems W, te Koppele J, van der Linden S, Garnero P. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term

radiographic progression in patients with Rheumatoid arthritis.
Arthritis Rheum. 2004;50:1390-9.

64. Bruynesteyn K, Van Der Linden S, Landewé R, Gubler F, Weijers R, Van der Heijde D. Progression of rheumatoid arthritis on plain radiographs judged differently by expert radiologists and rheumatologists. J Rheumatol 2004;31:1088-94.

63. Bruynesteyn K, Wanders A, Landewé R, Van Der Heijde D. How the type of risk reduction influences required sample sizes in randomized clinical trials. Ann Rheum Dis. 2004;63:1368-71.

62. Welsing PM, Landewé RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, Swinkels HL, van der Heijde DM. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum. 2004;50:2082-93.

61. Wanders AJ, Landewé RB, Spoorenberg A, De Vlam K, Mielants H, Dougados M, Van Der Linden S, Van Der Heijde DM. Scoring of radiographic progression in randomised clinical trials in ankylosis spondylitis: a preference for paired reading order. Ann Rheum Dis. 2004;63:1601-4.

60. Wanders AJ, Landewé RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, van der Tempel H, van der Heijde DM. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum. 2004;50:2622-32.

59. Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum. 2004;51:154-9

58. Heuft-Dorenbosch L, Vosse D, Landewé R, Spoorenberg A, Dougados M, Mielants H, Van Der Tempel H, Van Der Linden S, Van Der Heijde D. Measurement of Spinal Mobility in Ankylosing Spondylitis: Comparison of Occiput-to-Wall and Tragus-to-Wall Distance. J Rheumatol. 2004;31:1779-84.

2003

57. de Klerk E, van der Heijde D, Landewé R, van der Tempel H, van der Linden S. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol. 2003;30:2469-75.

56. Landewé R, van de Heijde D. Is radiographic progression a realistic outcome measure in clinical trials with early inflammatory arthritis? Clin Exp Rheumatol. 2003;21(Suppl 31):S37-41.

55. Garnero P, Geusens P, Landewé R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21(Suppl 31):S54-8.

54. Schulpen GJC, Vierhout WPM, van der Heijde DM, Landewé RB, winkens RAG, van der Linden SJ. Joint consultation of general practitioner and rheumatologist: does it matter? Ann Rheum Dis. 2003;62:159-161.

53. Garnero P, Geusens P and Landewé RB. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheum. 2003;21(suppl 31):S54-S59.

52. Landewé RB, van der Heijde, D. Is radiographic progression a realistic outcome measure in clinical

trials with early inflammatory arthritis?
Clin Exp Rheum. 2003;21(suppl31):S37-S42.

51. van der Heijde D, Landewé R. Imaging: Do erosions heal? Ann Rheum Dis. 2003;62(suppl2):10-12.
Landewé RB, van der Heijde, D. Early rheumatoid arthritis: Towards tailor-made therapy.
Curr Rheumatol Rep. 2003;5:287-93.

50. de Klerk E, van der Heijde D, van der Tempel H, Landewé R, van der Linden Sj. The compliance questionnaire rheumatology compared with electronic medication event monitoring: a validation study.
J Rheumatol. 2003;30:2469-75.

49. Schulpen GJC, Vierhout WPM, van der Heijde DM, Landewé RB, Winkens RAG, van der Linden SJ. Joint consultation of general practitioner and rheumatologist: does it matter? A
nn Rheum Dis. 2003;62:159-161.

48. Landewé RB. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing.
Arthritis Rheum. 2003;48:1-5.

47. Vanhoof J, Landewé R, Vandevenne J, Geusens P. An exceptional radiographic presentation of bilateral insufficiency fractures of the proximal tibia in a patient with rheumatoid arthritis.
Ann Rheum Dis. 2003;62:277-9.

46. Gerards AH, Landewé RB, Prins AP, Bruijn GA, Goei The HS, Laan RF, Dijkmans BA. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial.
Ann Rheum Dis. 2003;62:291-6.

45. Delen S, Boonen A, Landewé R, Kroon A, van der Linden Sj, Cohen Tervaert JW. An unusual case of ANCA positive disease.
Ann Rheum Dis. 2003;62:780-781.

44. Boonen A, van der Heijde D, Landewé R, Guillemin F, Rutten-van Mólken M, Dougados M, Mielants H, de Vlam K, van der Tempel H, boessen S, Spoorenberg A, Schouten H, van der Linden Sj. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.
Ann Rheum Dis. 2003;62:732-740.

43. Boonen A, van der Heijde D, Landewé R, Guillemin F, Spoorenberg A, Schouten H, Rutten-van Mólken M, Dougados M, Mielants H, de Vlam K, van der Tempel H, van der Linden Sj. Costs of ankylosing spondylitis in three European countries: the patient's perspective.
Ann Rheum Dis. 2003; 62:741-747.

42. Landewé R, van der Heijde D. Principles of assessment from a clinical perspective.
Best Pract Res Clin Rheumatol. 2003;17:365-79.

41. van Tubergen A, van der Heijde D, Anderson J, Landewé R, Dougados M, Braun J, Bellamy N, Udreá G, van der Linden S for the ASAS Working Group. Comparison of ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel.
Ann Rheum Dis. 2003;62:215-221.

40. van Tubergen A, Heuft-Dorenbosch L, Schulpen G, Landewé R, Wijers R, van der Heijde D, van Engelshoven J, van der Linden Sj. Radiographic assessment of sacroiliitis by radiologists and rheumatologists: Does training improve quality?
Ann Rheum Dis. 2003;62:519-525.

39. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van der Tempel H, Mielants H, Dougados M, van der Heijde D. Assessment of enthesitis in ankylosing spondylitis.
Ann Rheum Dis. 2003;62:127-32.

38. van Tubergen A, Landewé R, Heuft L, Spoorenberg A, van der Heijde D, van der Tempel H, van der Linden S. Assessment of disability with the WHODAS II in patients with ankylosing spondylitis. *Ann Rheum Dis* 2003;62:140-5

37. Landewé R, Boers M, van der Heijde D. How to interpret radiologic progression in randomised clinical trials? *Rheumatology* 2003;42:2-5.

36. de Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica and gout. *J Rheumatol* 2003;30:44-54.

2002

35. Landewé RB, Breedveld FC, Dijkmans BA. Methotrexate treatment and mortality in rheumatoid arthritis. *Lancet*. 2002;360:1095-6.

34. Santen van M, Bolwijn P, Landewé R, Verstappen F, Bakker C, Hidding A, van der Heijde D, Houben H, van der Linden S. High or low intensity aerobic fitness training in fibromyalgia. Does it matter? *J Rheumatol*. 2002;29:582-7.

33. van Tubergen A, Boonen A, Landewé R, van Molken-Rutten M, van der Heijde D, Hidding A, van der Linden S. Cost-effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomised controlled trial. *Arthritis Rheum*. 2002;47:459-67.

32. Garnero P, Landewé R, Boers M, Verhoeven A, van der Linden S, Christgau S, van der Heijde D, Boonen A, Geusens P. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis. *Arthritis Rheum*. 2002;46:2847-56.

31. Boonen A, Chorus A, Landewé R, Heijde DMFM van der, Miedema H, Tempel H, Linden van der S. Manual jobs increase the risk of patients with ankylosing spondylitis withdrawing from the labour force, also when adjusted for job related withdrawal in the general population. *Ann Rheum Dis*. 2002;61:658.

30. Strand V, Landewé R, van der Heijde D. Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis. *Ann Rheum Dis*. 2002;61(suppl II):ii64-ii66.

29. Boonen A, van der Heijde D, Landewé R, Spoorenberg A, Schouten H, Rutten-van Mólken M, Guillemin F, Dougados M, Mielants H, de Vlam K, van der Tempel H, van der Linden SJ. Work-status and productivity costs due to Ankylosing Spondylitis: comparison among three European countries. *Ann Rheum Dis*. 2002;61:429-37.

28. Landewé R, Boers M, Verhoeven A, Westhovens R, van de Laar M, Markusse H, van Denderen C, Westedt M, Peeters A, Dijkmans B, Jacobs P, Boonen A, van der Heijde D, van der Linden S. COBRA-combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. *Arthritis Rheum*. 2002;2:347-56.

27. Landewé R, van der Heijde D. Follow-up studies in rheumatoid arthritis. *Ann Rheum Dis*. 2002;61:479-81.

26. van Tubergen A, Debats I, Ryser L, Londonõ J, Burgos-Vargas R, Cardiel M, Landewé R, Stucki G, van der Heijde D. The use of a numerical rating scale as an answer modality in ankylosing spondylitis specific questionnaires. *Arthritis Rheum*. 2002;47:242-8.

25. van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, van der Linden Sj, van der Heijde D. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. *Arthritis Rheum.* 2002;47:8-16.

24. van Santen M, Bolwijn P, Verstappen F, Bakker C, Hidding A, Houben H, van der Heijde D, Landewé R, van der Linden S. A randomized clinical trial comparing fitness and biofeedback training versus basic treatment in patients with fibromyalgia. *J Rheumatol.* 2002;29:575-81.

2001

23. Verburg RJ, Sont JK, Vliet Vlieland TP, Landewé RB, Boers M, Kievit J, van Laar JM. High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis. *J Rheumatol.* 2001;28:719-27.

22. van Tubergen AM, Landewé RB, van der Linden S: Spondylarthropathies: options for combination therapy. *Springer Semin Immunopathol.* 2001;23: 47-63.

21. Boonen A, Chorus A, Miedema H, van der Heijde D, Landewé R, Schouten H, van der Tempel H, van der Linden Sj. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. *Ann Rheum Dis.* 2001;60:1033-9.

20. van Tubergen A, Landewé R, van der Heijde D, Hidding A, Wolter N, Asscher M, Falkenbach A, Genth E, Goei Thè H, van der Linden S. Combined spa-exercise therapy is effective in ankylosing spondylitis: a randomized controlled trial. *Arthritis Rheum.* 2001;45:430-8.

1999

19. Dijkmans BA, Landewé RB, van den Borne BE, Breedveld FC: Combination cyclosporine and (hydroxy)chloroquine in rheumatoid arthritis. *Clin Exp Rheumatol.* 1999;17(Suppl 18):S103-4.

18. van den Borne BEEM, Landewé RBM, Goei The HS, Breedveld FC, Dijkmans BAC: Cyclosporine A therapy in rheumatoid arthritis: Only strict application of the guidelines for safe use can prevent irreversible renal function loss. *Rheumatology.* 1999;1:254-9.

17. van den Borne BEEM, Landewé RBM, Rietveld JH, Goei The HS, Griep EN, Breedveld FC, Dijkmans BAC: Chloroquine therapy in patients with recent onset rheumatoid arthritis: The clinical response can be predicted by the level of acute phase reaction at baseline. *Clin Rheumatol.* 1999;18:369-72.

1998

16. Wolthuis A, Landewé RBM, Theunissen PHMH, Westerhuis LWJM: Chylothorax or leakage of total parenteral nutrition? *Eur Respiratory J.* 1998;12:1233-5.

15. van den Borne BEEM, Landewé RBM, Houkes I, Schild F, van der Heyden PCW, Hazes JMW, van den Broucke JP, Zwinderman AH, Goei The HS, Breedveld FC, Bernelot Moens HJ, Kluyn Ph, Dijkmans BAC: No increased risk of malignancies and mortality in cyclosporine-A treated rheumatoid arthritis patients. *Arthritis Rheum.* 1998;41:1930-8.

14. van den Borne BEEM, Landewé RBM, Goei The HS, Rietveld JH, Zwinderman AH, Bruyn GAW, Breedveld FC, Dijkmans BAC: Combinationtherapy in recent onset rheumatoid arthritis: a synergistical interaction between chloroquine and cyclosporine. *J Rheumatol.* 1998;25:1493-8.

1996

13. Dijkmans BAC, van den Borne BE, Landewé R, Miltenburg AM, Verweij CI, Breedveld FC: Chloroquine combined with cyclosporine in rheumatoid arthritis: more than the addition of 2 drugs alone. *J Rheumatol.* 1996;44 (suppl):61-3.

12. RBM Landewé, BAC Dijkmans, MJA Verdonk, CL Verwey, FC Breedveld, MR Daha, AMM Miltenburg: TCR/CD3-crosslinking downregulates IL-2 responsiveness in IL-2-competent CD4-positive cloned T-cells. Evidence for the involvement of protein kinase C. *Scand J Immunol.* 1996;44:45-53.

11. BEEM van den Borne, RBM Landewé, HS Goei The, FC Breedveld, BAC Dijkmans. Low dose cyclosporine in early rheumatoid arthritis: Effective and safe after two years of therapy when compared to chloroquine. *Scand J Rheum.* 1996;25: 307-16.

10. RBM Landewé, BAC Dijkmans, FJ van der Woude, FC Breedveld, MJ Mihatsch, JA Bruijn: Long term low-dose cyclosporine in patients with rheumatoid arthritis. Renal function loss without structural nephropathy. *J Rheumatol.* 1996;23:61-5.

1995

9. RBM Landewé, AMM Miltenburg, MJA Verdonk, CL Verwey, FC Breedveld, MR Daha, BAC Dijkmans: Chloroquine inhibits T-cell proliferation by interference with IL-2 production and responsiveness. *Clin Exp Immunol.* 1995;102:144-51.

8. RBM Landewé, MS Vergouwen, HS Goei The, AWAM van Rijthoven, FC Breedveld, BAC Dijkmans: Antimalarial drug induced decrease in creatinine clearance. *J Rheumatol.* 1995;22:34-7.

7. Borne van den BEEM, Landewé RBM, Goei The HS, Mattie H, Breedveld FC, Dijkmans BAC: Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis. *Br J Clin Pharmacol.* 1995;39:172-175.

6. Dijkmans BAC, Landewé RBM, Goei The HS, Rijthoven AWAM van, Breedveld FC. Indications and use of cyclosporin A in rheumatic diseases. *Rheum Eur* 1995;46:72-72.

1994

5. Landewé RBM, Goei The HS, van Rijthoven AWAM, Rietveld JR, Breedveld FC, Dijkmans BAC: Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis. *J Rheumatol.* 1994;21:1631-1636.

4. Landewé RBM, Goei The HS, van Rijthoven AWAM, Breedveld FC, Dijkmans BAC: A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. *Arthritis Rheum.* 1994;37:637-643.

1993

3. Dijkmans BAC, Landewé RBM, van Rijthoven AWAM, Goei The HS: Cyclosporine in rheumatoid arthritis (RA): state of the art, with emphasis on the treatment of early RA. *Rheumatismo* 1993;44 Supp:35-42.

1992

2. RBM Landewé, AMM Miltenburg, FC Breedveld, MR Daha, BAC Dijkmans: Cyclosporine and chloroquine synergistically inhibit the interferon gamma production by CD4 positive and CD8 positive synovial T-cell clones derived from a patient with rheumatoid arthritis. *J Rheumatol.* 1992;19:1353-7.

1989

1. RBM Landewé, HS Goei. The Ankylosing spondylitis and peripheral joint disease. Clin Rheumatol. 1989;8:87-90.

2. Thesis

The optimization of cyclosporin A therapy in rheumatoid arthritis, 24 februari 1994, Rijksuniversiteit Leiden.

3. Letters to the editor

5. van Eijk-Hustings Y, Boonen A, Landewé R. A randomized trial of tai chi for fibromyalgia. N Engl J Med. 2010;363:2266; author reply 2266-7.

4. Gerards AH, Dijkmans BAC, Landewé RBM. Authors' reply on Cyclosporin and methotrexate therapy. Ann Rheum Dis. 2003;62:1121-3.

3. Landewé RB. Reply to comments by Jacobs and Bijlsma. Arthritis Rheum

2. Landewé RB. Reply to comments by McEntegart and Madhok. Arthritis Rheum 2003;48:272-3

1. Landewé RBM, van den Borne BEEM, Breedveld FC, Dijkmans BAC: Does cyclosporine-A cause cancer? Nature Med 1999;7:714-5

4. Scientific Dutch full-length papers

5. Landewé RBM, van der Heijde DMFM. Het herkennen van patienten met spondyloarthritis. Nieuwe classificatiecriteria. Ned Tijdschr Geneesk. 2011;155:A3680

4. Schulpen GJ, Vierhout WP, van der Heijde DM, Landewé RB, van der Linden S, Winkens RA. [The value of joint general practitioner and rheumatologist consultations in primary care patients]. Ned Tijdschr Geneesk. 2003;8;147(10):447-50. Dutch

3. Landewé, RB. De mortaliteit van reumatoïde artritis. Ned Tijdschr Reumatologie, januari 2002.

2. Landewé R, van der Heijde D. Een doorbraak voor Bechterew-patiënten. Infliximab opent indrukwekkende behandelperspectieven. Medisch Contact. 2002;57:1187-90.

1. RBM Landewé, R Peeters, RL Verreussel, BA Masek, HS Goei The: Geen verschil in effectiviteit gemeten tussen behandeling in een thermaalbad en in een oefenbad bij patienten met reumatoïde artritis. Ned Tijdschr Geneesk 1992;136: 173-6.